Conditions: Atopic Dermatitis
Allocation: NON_RANDOMIZED | Intervention model: SEQUENTIAL
Enrollment: 38
Healthy volunteers: no

Brief summary:
A Phase 2 study of Bermekimab (MABp1) in patients with atopic dermatitis.

Detailed description:
A Phase 2, Open Label, Dose Escalation Study of Bermekimab (MABp1) in Patients with Moderate to Severe Atopic Dermatitis. The study is multi center and will consist of two dose levels:

Group A (n=9): patients will receive a total of 4 x 200mg subcutaneous injections of bermekimab. Dosing will occur weekly from visit 1 to visit 4, inclusive.

Group B (n=20): patients will receive a total of 8 x 400 mg subcutaneous injections of bermedimkb. Dosing will occur weekly from visit 1 to visit 8, inclusive.

Arms:
arm 1: The dose of bermekimab for Group A is 200 mg (2ml of the 100 mg/ml formulation) arm 2: The dose of bermekimab for Group B is 400 mg (2ml of the 200 mg/ml formulation) administered weekly by subcutaneous injection

Interventions: intervention 1: Bermekimab Monoclonal Antibody 200 mg intervention 2: Bermekimab Monoclonal Antibody 400 mg
Intervention descriptions: intervention 1: 200 mg subcutaneous injection intervention 2: 400 mg subcutaneous injection

Protocol document:
Prot_SAP_000.pdf: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Trial Protocol 
A Phase II, Open Label, Dose Escalation Study of 
Bermekimab (MABp1) in Patients with Moderate to 
Severe Atopic Dermatitis 
SPONSOR 
XBiotech USA Inc 
 
 
 
 
 
 
 
 
22 August 2018 


XBIOTECH USA INC.            
 
PROTOCOL 2018-PT044 Version 3.0 
CONFIDENTIAL                                        22 August  2018                                            PAGE 2 of 52 
 
Basic Information ........................................................................................................................... 4 
Investigator/Sponsor Signatures ................................................................................................... 5 
Abbreviations ............................................................................................................................... 11 
1.  BACKGROUND ..................................................................................................................... 12 
1.1 Overview .............................................................................................................................. 12 
1.2 Rationale .............................................................................................................................. 13 
2.  INVESTIGATIONAL PRODUCT ........................................................................................ 14 
2.1 Active Ingredient, Pharmacologic Class, Structure ............................................................ 14 
2.2 Drug Product (Bermekimab 100 mg/ml) Description ......................................................... 15 
2.3 Drug Product (Bermekimab 200 mg/ml) Description ......................................................... 16 
2.4 STORAGE ............................................................................................................................ 16 
2.5 Stability ................................................................................................................................ 17 
2.6 Method of Administration .................................................................................................... 17 
2.7 Ordering Of Study Drug ...................................................................................................... 18 
2.8 Potential Drug Interactions ................................................................................................. 19 
2.9 Concomitant Medications and Procedures ......................................................................... 19 
2.9.1 Prohibited and Restricted Therapies ............................................................................. 19 
2.9.2 Permitted Medications and Procedures ........................................................................ 20 
3.  STUDY DESIGN AND OBJECTIVES ................................................................................. 20 
3.1 Study Endpoints ................................................................................................................... 21 
4.  ELIGIBILITY CRITERIA .................................................................................................... 23 
4.1 Inclusion Criteria ................................................................................................................ 23 
4.2 Exclusion Criteria ................................................................................................................ 24 
5.   TREATMENT PLAN ............................................................................................................ 26 
5.1 Study Procedures ................................................................................................................. 26 
5.2 Study Calendar .................................................................................................................... 32 
5.3 Dose escalation rules ........................................................................................................... 33 
5.4 Rescue Treatment(s) ............................................................................................................ 33 
5.5 Discontinuation of Therapy ................................................................................................. 34 
5.6 Trial Stopping Rules ............................................................................................................ 34 
6.  CORRELATIVE STUDIES ................................................................................................... 35 
6.1 PHARMACOKINETICS (PK) SAMPLE COLLECTION ..................................................... 35 
7.  ASSESSMENT OF SAFETY ................................................................................................. 35 
8.  STUDY VARIABLES ............................................................................................................. 36 
8.1 DEMOGRAPHIC AND DISEASE CHARACTERISTICS .................................................... 36 
8.2 STUDY ENDPOINT DEFINITIONS ................................................................................... 36 
Eczema Area and Severity Index .......................................................................................... 36 
Pharmacokinetic Assessment ................................................................................................ 36 
Investigator’s Global Assessment ......................................................................................... 36 
Global Individual Signs Score ............................................................................................... 36 
SCORing Atopic Dermatitis .................................................................................................. 37 
Patient Assessment of Pruritus and Pain ............................................................................... 37 
Visit 1 Questionnaire for Pruritus, Pain and Erythema ......................................................... 37 
Patient Oriented Eczema Measure ........................................................................................ 38 
Hospital Anxiety and Depression Scale ................................................................................ 38 
Dermatology Life Quality Index ........................................................................................... 38 


XBIOTECH USA INC.            
 
PROTOCOL 2018-PT044 Version 3.0 
CONFIDENTIAL                                        22 August  2018                                            PAGE 3 of 52 
 
9.  ADVERSE EVENTS .............................................................................................................. 39 
9.1 Definition of Adverse Event (AE) ........................................................................................ 39 
9.2 Definition of Serious Adverse Event (SAE) ......................................................................... 39 
9.3 Recording of Adverse Events ............................................................................................... 40 
9.4 Evaluating Adverse Events .................................................................................................. 40 
9.5 Assessment of Causality ....................................................................................................... 40 
9.6 Reporting Requirements ...................................................................................................... 41 
9.7 reference safety information:  potential adverse reactions ................................................. 41 
10.  STATISTICAL PLAN .......................................................................................................... 43 
10.1 Statistical Hypothesis ........................................................................................................ 43 
10.2 Determination of Sample Size ............................................................................................ 43 
10.3 Analysis Sets ...................................................................................................................... 43 
10.3.1 Safety Analysis Sets ................................................................................................... 43 
10.4 Patient Disposition ............................................................................................................ 43 
10.5 Statistical Methods ............................................................................................................ 44 
10.5.1 Handling Missing Data ............................................................................................... 44 
10.5.2 Adjustment for Multiple Comparisons ....................................................................... 44 
10.5.3 Demography and Baseline Characteristics ................................................................. 44 
10.5.4 Efficacy Analysis ....................................................................................................... 44 
10.6 Safety Analysis ................................................................................................................... 45 
10.6.1 Analysis of Adverse Events ....................................................................................... 45 
10.6.2 Other Safety................................................................................................................ 45 
10.7 PK Analysis........................................................................................................................ 46 
10.7.1 Treatment Exposure ................................................................................................... 46 
11.  STUDY MANAGEMENT AND ADMINISTRATION ..................................................... 47 
11.1 Ethical Conduct of Study (GCP)........................................................................................ 47 
11.2 IRB and Ethics committee Approval .................................................................................. 47 
11.3 Protocol Modifications ...................................................................................................... 47 
11.4 Subject Information and Consent ...................................................................................... 48 
11.5 Data Protection and Confidentiality ................................................................................. 48 
11.6 Study Report and Publications .......................................................................................... 49 
11.7 Study Files and Retention of Records ................................................................................ 49 
11.8 Case Report Forms ............................................................................................................ 49 
11.9 Drug Accountability .......................................................................................................... 49 
11.10   Inspections ..................................................................................................................... 50 
11.11 Access to Information for Monitoring ............................................................................. 50 
11.12 Study Discontinuation ...................................................................................................... 51 
REFERENCES ............................................................................................................................. 52 
 
 
 


XBIOTECH USA INC.            
 
PROTOCOL 2018-PT044 Version 3.0 
CONFIDENTIAL                                        22 August  2018                                            PAGE 4 of 52 
 
Basic Information 
 
STUDY TITLE: A Phase II, Open Label, Dose Escalation Study of Bermekimab 
(MABp1) in Patients with Moderate to Severe Atopic Dermatitis 
 
INVESTIGATIONAL PRODUCT: 
Bermekimab (MABp1) 
 
IND NUMBER: 
 
 
 
112,459 
 
 
 
 
 
 
 
 
PROTOCOL NUMBER: 
 
 
2018-PT044  
 
 
 
 
PROTOCOL VERSION / DATE:  
3.0/ 22 August 2018  
 
 
 
 
SPONSOR:  
 
 
 
XBiotech USA, Inc.  
5217 Winnebago Lane 
Austin, Texas 78744 U.S.A. 
Phone: 737-207-4600 
 
SPONSOR’S MEDICAL OFFICER: 
Mark Williams M.D., MBA 
XBiotech USA, Inc.  
5217 Winnebago Lane 
Austin, Texas 78744 U.S.A. 
Phone: 737-207-4612 
 
STUDY CHAIR  
Francisco Armando Kerdel, M.D 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


XBIOTECH USA INC.            
 
PROTOCOL 2018-PT044 Version 3.0 
CONFIDENTIAL                                        22 August  2018                                            PAGE 5 of 52 
 
Investigator/Sponsor Signatures 
 
STUDY TITLE:  A Phase II, Open Label, Dose Escalation Study of Bermekimab (MABp1) in 
Patients with Moderate to Severe Atopic Dermatitis 
 
STUDY PRINCIPAL INVESTIGATOR SIGNATURE:  
I have read the protocol and appendices. I understand the contents and intend to comply fully with 
all requirements and the applicable current local and international regulations and guidelines. No 
changes will be made without formal authorization by XBiotech USA, Inc., in the form of a 
protocol amendment. 
 
INVESTIGATOR SIGNATURE: 
 
 
_____________________________________________  
Printed name of Investigator  
 
 
_____________________________________________  
Signature  
 
 
_____________________________________________  
Date  
 
 
SPONSOR SIGNATURE:  
XBiotech USA, Inc. 
 
Mark Williams M.D., MBA, Medical Director 
 
 
____________________________________________  
Signature 
 
 
____________________________________________  
Date 


XBIOTECH USA INC.            
 
PROTOCOL 2018-PT044 Version 3.0 
CONFIDENTIAL                                        22 August  2018                                            PAGE 6 of 52 
 
Clinical Protocol Synopsis 
Study Title: A Phase II, Open Label, Dose Escalation Study of Bermekimab (MABp1) in Patients 
with Moderate to Severe Atopic Dermatitis  
 
 
 
 
Sponsor:   
 
 
 
 
XBiotech USA, Inc. 
Study Chair:   
Francisco Armando Kerdel M.D 
Sample Size: 
 
29 Subjects  
 
Approximate Duration:  The study duration of subject participation is approximately 10 weeks, 
including a 2 week screening period, a 7 week treatment period, and 1 week follow up period.  
 
Study Objectives: 
Primary Endpoint(s): 
• 
Safety and Tolerability 
 
Secondary Endpoints: 
• 
Change in Eczema Area and Severity Index Score (EASI) from baseline to visit 8   
• 
Assessment of Pharmacokinetics (PK)  
• 
Patients (%) achieving Investigator's Global Assessment (IGA) Response (0 or 1) at visit 
8  
• 
Patients (%) achieving ≥2 IGA Score Reduction at visit 8 
• 
Change (%) for peak weekly averaged pruritus and pain numerical rating scores (NRS) 
from baseline to visit 8 
• 
Change in weekly averaged peak NRS from baseline to visit 8 
• 
Change in SCORing Atopic Dermatitis (SCORAD) score from baseline to visit 8  
• 
Patients (%) achieving 50% or greater reduction in EASI Score from baseline at visit 8 
• 
Patients (%) achieving 50% or greater reduction in SCORAD Score at visit 8 
• 
Change (%) in Patient Oriented Eczema Measure (POEM) Scores from baseline to visit 8 
• 
Changes in Global Individual Signs Score (GISS) from baseline to visit 8 
• 
Change from baseline to visit 8 in Dermatology Life Quality Index (DLQI) 
• 
Change from baseline to visit 8 in Hospital Anxiety Depression Scale (HADS) 


XBIOTECH USA INC.            
 
PROTOCOL 2018-PT044 Version 3.0 
CONFIDENTIAL                                        22 August  2018                                            PAGE 7 of 52 
 
• 
Change (%) from pre- and post- injection of Visit 1 Questionnaire for pruritus, pain and 
erythema 
 
Trial Design: 
Phase 2, Open label, Dose Escalation Study of Bermekimab (MABp1) in Patients with 
Moderate to Severe Atopic Dermatitis. 
 
Group A (n=9): patients will receive a total of 4 X 200mg subcutaneous injections of 
bermekimab. Dosing will occur weekly from visit 1 to visit 4. 
 
Group B (n=20): patients will receive a total of 8 X 400mg subcutaneous injections of 
bermekimab. Dosing will occur weekly from visit 1 to visit 8.  
 


XBIOTECH USA INC.            
 
PROTOCOL 2018-PT044 Version 3.0 
CONFIDENTIAL                                        22 August  2018                                            PAGE 8 of 52 
 
Inclusion Criteria:  
No waivers/exemptions will be granted for protocol inclusion/exclusion criteria. 
 
Subjects are included in the study if they meet all of the following criteria: 
• 
Documented recent history (within 6 months before the screening visit) of inadequate 
response to treatment with topical medications or for whom topical treatments are otherwise 
medically inadvisable or undesired 
 
 
• 
Written informed consent provided by the patient 
• 
Age ≥18 years 
• 
Chronic Atopic Dermatitis present for at least 3 years 
• 
Disease is not responsive to topical medications, or for whom topical treatments are not 
indicated or desired 
• 
Willing and able to comply with all clinic visits and study-related procedure 
• 
EASI score ≥16 at screening and baseline visits 
• 
IGA score ≥3 at screening and baseline visits 
• 
≥10% body surface area (BSA) of AD involvement at screening and baseline visits 


XBIOTECH USA INC.            
 
PROTOCOL 2018-PT044 Version 3.0 
CONFIDENTIAL                                        22 August  2018                                            PAGE 9 of 52 
 
Exclusion Criteria: 
Subjects with ANY of the following will be excluded from the study: 
• 
Treatment with an investigational drug within 8 weeks of baseline visit 
• 
Having received the following treatments within 4 weeks before the baseline visit, or any 
condition that, in the opinion of the investigator, is likely to require such treatment(s) during 
the first 4 weeks of study treatment:   
a. Immunosuppressive/immunomodulating drugs (eg, systemic corticosteroids, 
cyclosporine, mycophenolate-mofetil, IFN-γ, Janus kinase inhibitors, 
azathioprine, methotrexate, etc.) 
b. Phototherapy for AD 
• 
Treatment with topical corticosteroids (TCS) or topical calcineurin inhibitors (TCI) within 1 
week before the baseline visit 
• 
Initiation of treatment during the screening period with prescription moisturizers or 
moisturizers containing additives such as ceramide, hyaluronic acid, urea, or filaggrin 
degradation products during the screening period (patients may continue using stable doses 
of such moisturizers if initiated before the screening visit) 
• 
Regular use (more than 2 visits per week) of a tanning booth/parlor within 4 weeks of the 
screening visit 
• 
History of severe allergic or anaphylactic reactions to monoclonal antibodies 
• 
Administration of any live (attenuated) vaccine within 4 weeks prior to the baseline 
• 
Any history of dysplasia or history of malignancy (including lymphoma and leukemia) other 
than a successfully treated non-metastatic cutaneous squamous cell carcinoma, basal cell 
carcinoma or localized carcinoma in situ of the cervix 
• 
Active chronic or acute infection requiring treatment with systemic antibiotics, antivirals, 
antiparasitics, antiprotozoals, or antifungals within 2 weeks before the baseline visit, or 
superficial skin infections within 1 week before the baseline visit. NOTE: patients may be 
rescreened after infection resolves 
• 
Known or suspected history of immunosuppression, including history of invasive 
opportunistic infections (eg, tuberculosis [TB], histoplasmosis, listeriosis, 
coccidioidomycosis, pneumocystosis, aspergillosis) despite infection resolution: or unusually 
frequent, recurrent, or prolonged infections, per investigator judgment 
• 
History of human immunodeficiency virus (HIV) infection or positive HIV serology at 
screening 
• 
Positive with hepatitis B surface antigen (HBsAg) or hepatitis C antibody at the screening 
visit 
• 
Presence of skin comorbidities that may interfere with study assessments 


XBIOTECH USA INC.            
 
PROTOCOL 2018-PT044 Version 3.0 
CONFIDENTIAL                                        22 August  2018                                            PAGE 10 of 52 
 
• 
Where relevant, women unwilling to use adequate birth control 
 
 
• 
Severe concomitant illness(es) that, in the investigator’s judgment, would adversely affect 
the patient’s participation in the study. Examples include, but are not limited to, patients with 
short life expectancy, patients with uncontrolled diabetes (HbA1c ≥ 9%),  patients with 
cardiovascular conditions (eg, stage III or IV cardiac failure according to the New York 
Heart Association classification), severe renal conditions (eg, patients on dialysis), 
hepatobiliary conditions (eg, Child-Pugh class B or C), neurological conditions (eg, 
demyelinating diseases), active major autoimmune diseases (eg, lupus, inflammatory bowel 
disease, rheumatoid arthritis, etc.), other severe endocrinological, gastrointestinal, metabolic, 
pulmonary or lymphatic diseases. The specific justification for patients excluded under this 
criterion will be noted in study documents (chart notes, case report forms [CRFs], etc.) 
• 
Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed 
during the study 


XBIOTECH USA INC.            
 
PROTOCOL 2018-PT044 Version 3.0 
CONFIDENTIAL                                        22 August  2018                                            PAGE 11 of 52 
 
Abbreviations 
 
AD 
 
Atopic Dermatitis 
AE 
 
Adverse event 
ALT 
 
Alanine aminotransferase (ALT, SGPT) 
PT/aPTT  
Prothrombin Time/Activated Partial Thromboplastin Time 
ALP 
 
Alkaline phosphate 
BMI 
 
Body mass index 
BP 
 
Blood pressure 
BSA 
 
Body Surface Area 
CBC 
 
Complete blood counts 
CI 
 
Confidence interval 
CH 
 
Heavy chain constant region 
CL 
 
Light chain constant region 
eCRF 
 
Electronic Case report form 
CRA 
 
Clinical Research Associate 
CRP 
 
C-Reactive Protein 
CTCAE  
Common terminology criteria for adverse events 
DLQI 
 
Dermatology Life Quality Index 
EASI 
 
Eczema Area and Severity Index Score 
EC 
 
Ethics Committee 
ECG 
 
Electrocardiogram 
ELISA 
 
Enzyme-linked immunosorbent assay 
GISS 
 
Global Individual Signs Score 
GCP 
 
Good clinical practice 
GLP 
 
Good laboratory practice 
GMP 
 
Good manufacturing practice 
HADS 
 
Hospital Anxiety Depression Scale 
HbA1c 
 
Hemoglobin A1c 
HBsAg  
Hepatitis B surface antigen 
HIV 
 
Human immunodeficiency virus 
IFN-γ 
 
Interferon Gamma 
IGA 
 
Investigator’s Global Assessment 
IGRA 
 
Interferon Gamma Release Assay 
IgG 
 
Immunoglobulin G 
IL-1 α 
 
Interleukin-1 α 
IL-1β  
 
Interleukin-1 β 
IL-1 RA  
Interleukin-1 receptor antagonist 
IRB 
 
Institutional review board 
NRS 
 
Pruritus numerical rating score 
POEM 
 
Patient Oriented Eczema Measure 
pI  
 
Isoelectric Point 
PK 
 
Pharmacokinetics 
SAE 
 
Serious Adverse Event 
SCORAD 
Severity Scoring of Atopic Dermatitis 
TB 
 
Tuberculosis 
TCI 
 
Topical calcineurin inhibitor 
TCS 
 
Topical corticosteroid 
ULN 
 
Upper limit of normal 
UV 
 
Ultraviolet 
VAS 
 
Visual Analogue Scale 
WOCBP  
Women of childbearing potential 
 


XBIOTECH USA INC.            
 
PROTOCOL 2018-PT044 Version 3.0 
CONFIDENTIAL                                        22 August  2018                                            PAGE 12 of 52 
 
1.  BACKGROUND 
 
1.1 OVERVIEW 
XBiotech USA, Inc. has developed a True Human monoclonal antibody, bermekimab, that binds 
the cytokine IL-1α with high affinity and is an effective blocker of IL-1α biological activity. IL-
1α is a key mediator of sterile inflammatory responses and has been implicated in the pathology of 
advanced cancer, cardiovascular disease, and rheumatologic disease. Clinical evidence generated 
to date suggests that targeting IL-1α may be an effective treatment in undermining the 
inflammatory process that drives a wide array of diseases, including dermatologic conditions. 
 
The active ingredient in the drug product is bermekimab, a recombinant human IgG1 monoclonal 
antibody specific for human interleukin-1α (IL-1α). The entire bermekimab heavy and light chain 
sequences are identical to those found in naturally-occurring human IgG1κ, with the light and 
heavy chain variable regions being identical to those originally expressed by a peripheral blood B 
lymphocyte that was obtained from a healthy individual. No in vitro affinity maturation or 
modifications have been made to improve its natural binding affinity (211 +/- 31 pM). We believe 
that a true human antibody should be effectively non-immunogenic in humans and thus exhibit 
optimal activity and pharmacokinetics.  XBiotech has conducted 10 clinical studies to date using 
the bermekimab antibody.  These studies have been conducted in a wide range of therapeutic areas, 
from cancer to healthy volunteers, and have included a several different dose levels and dosing 
schedules. Both intravenous and subcutaneous formulations have been explored for safety and 
evidence of efficacy. 
 
Three phase 2 studies sponsored by XBiotech have been completed in dermatologic indications 
(acne, psoriasis, pyoderma gangrenosum), as well as one investigator sponsored study in 
Hidradenitis Suppurativa1,2,3.  Subjects with moderate to severe psoriasis experienced a rapid 
reduction in their psoriasis area and severity index (PASI), and subjects with acne vulgaris 
experienced reductions of inflammatory lesion counts, as well as reduced hospital anxiety and 
depression scores (HADS). In both of these trials, there were few adverse events, which were all 
grade 1 (mild) and the only events that appeared to be related to therapy were mild injection site 
reactions in two patients.  
 
The investigator initiated study enrolled patients with moderate to severe HS that were refractory 
to adalimumab.  The study was double blind, randomized and placebo controlled, and utilized the 


XBIOTECH USA INC.            
 
PROTOCOL 2018-PT044 Version 3.0 
CONFIDENTIAL                                        22 August  2018                                            PAGE 13 of 52 
 
Hidradenitis Suppurativa Clinical Response (HiSCR) score as a primary endpoint. Ten patients 
were randomized to placebo and 10 patients to treatment with bermekiamb.  A positive HiSCR 
score after 12 weeks was found in one (10%) and six (60%) patients respectively (OR: 13.50; 
95%CIs: 1.19-152.61; p: 0.035). After withdrawal of therapy at week 12, a positive HiSCR score 
was found in nil (0%) and four (40%) patients after 24 weeks (p: 0.043).   
 
Endogenous anti-IL-1α antibodies are present in 5% to 28% of the general population4,5,6,7.  No 
negative correlations with disease have been noted for these individuals. To the contrary, the 
presence of natural anti-IL-1α antibodies has been associated with favorable outcomes, both with 
respect to rheumatoid arthritis and ischemic heart disease. Animal studies also indicate that IL-1α 
loss or antagonism does not result in harm. Moreover, the well-tolerated use of other approved 
biological agents that employ other strategies to block IL-1 activity suggest that bermekimab’s 
targeting of IL-1α represents a safe treatment approach.  
 
1.2 RATIONALE 
Atopic dermatitis (AD) is an inflammatory skin disease affecting as much as 20% of the population 
in western industrial societies. Chronic eczema in AD and associated pruritus can be a significant 
cause of morbidity and impact life quality. Disease pathogenesis is complex but ultimately 
converges on a pathological inflammatory process that disrupts the protective barrier function of 
the skin.  
 
The prototypical inflammatory cytokine interleukin-1 alpha (IL-1⍺) plays a key role in the 
pathophysiology of a wide range of inflammatory skin disorders8.  Bermekimab is a natural human 
antibody that exhibits immunoregulatory activity through blocking IL-1⍺ activity. Keratinocytes 
are a major reservoir of IL-1⍺ and may be a key source of inflammatory stimulus in AD. IL-1⍺ is 
present on leukocytes, where its role in leukocyte trafficking and infiltration may represent a key 
step in the chronic inflammation of AD. IL-1⍺ is a key inducer of matrix metalloproteinases activity 
which could be directly involved in the epithelial barrier breakdown in AD9. Loss of regulation of 
IL-1 results in systemic inflammation with extensive skin involvement10. 
 
In previous dermatology studies bermekimab was well tolerated and showed impressive therapeutic 
activity. Dose ranging of the subcutaneous formulation of bermekimab is now being studied in a 6 
week open label treatment regimen for AD in order to establish the basis for further randomized 
studies. 


XBIOTECH USA INC.            
 
PROTOCOL 2018-PT044 Version 3.0 
CONFIDENTIAL                                        22 August  2018                                            PAGE 14 of 52 
 
2.  INVESTIGATIONAL PRODUCT 
2.1 ACTIVE INGREDIENT, PHARMACOLOGIC CLASS, STRUCTURE 
The active ingredient in the drug product is bermekimab, a recombinant human IgG1 monoclonal 
antibody specific for human interleukin-1α (IL-1α). The entire bermekimab heavy and light chain 
sequences are identical to those found in naturally-occurring human IgG1κ, with the light and 
heavy chain variable regions being identical to those originally expressed by a peripheral blood B 
lymphocyte that was obtained from a healthy individual. 
 
Figure 2.1: Bermekimab Antibody 
 
 
 
The bermekimab primary glycoform has a molecular weight of 148.1 kilodaltons. Like all IgG1 
molecules, the heavy chains are joined at their hinge regions through two disulfide linkages, and 
each heavy chain is joined to one light chain through one disulfide linkage between their CH1 and 
CL domains respectively. 
 
The main isoform has a pI of about 9.2 and comprises about 70-80% of the total isoform population 
in all lots that have been manufactured to date, as determined by capillary isoelectric focusing. The 
heavy chain CH2 domains are glycosylated primarily with the oligosaccharide structure shown in 
Figure 2.1, as determined by mass spectroscopy of the cleaved glycans. The glycosylated residue 
(Asn-302 as numbered from the N-terminus of bermekimab) has been determined by peptide 
mapping to be in the same highly conserved N-linked glycosylation site as found in endogenous 
IgG1 (Asn-297 according to the generic numbering system). Similarly, the primary glycan, 
commonly referred to as G0F, is the same as that found on about 22% of endogenous human IgG 
molecules11.  
 
The entire bermekimab heavy and light chain sequences are identical to those found in naturally-
occurring human IgG1κ, with the light and heavy chain variable regions being identical to those 
originally expressed by a peripheral blood B lymphocyte that was obtained from a healthy 
individual.   


XBIOTECH USA INC.            
 
PROTOCOL 2018-PT044 Version 3.0 
CONFIDENTIAL                                        22 August  2018                                            PAGE 15 of 52 
 
 
Endogenous anti-IL-1α antibody has been reported in 5% to 28% of healthy serum or plasma 
samples12,13. It has been measured in cord blood, children and adults14. The anti-IL-1α antibodies 
measured in human plasma have been strictly of the IgG class, particularly IgG1, IgG2, and IgG4. 
Relatively equal distribution is seen in male and female plasma15. Binding affinities reported for 
endogenous anti-IL-1α antibodies, ranging from 4 to 16 pM, are comparable to that for 
bermekimab, the specification for which is 22 to 260 pM. 
  
It is important to point out that affinity maturation had already taken place in the human host, and 
therefore no in vitro affinity maturation was required to increase the natural binding affinity of 
bermekimab. Also important is the fact that, unlike most other therapeutic IgG products, for which 
the Fc regions are derived from a rare human allele, XBiotech’s product includes a heavy chain in 
which the constant (CH) region represents an allele found in approximately 70% of the human 
population. These two features should make for a drug product with reduced potential for 
immunogenicity. 
 
2.2 DRUG PRODUCT (BERMEKIMAB 100 MG/ML) DESCRIPTION 
XBiotech’s dosage form is a sterile liquid formulation of 100 mg/mL bermekimab in a stabilizing 
isotonic subcutaneous formulation buffer at pH 6.2-6.5.   Each 2-mL Type I borosilicate glass 
serum vial contains 2 mL of the formulation and is sealed with a 13-mm Daikyo Flurotec butyl 
rubber stopper and flip-off aluminum seal.  The exact composition of the Drug Product is shown in 
the table below. 
 
Composition of Drug Product [100 mg/mL] 
Ingredient 
Ingredient 
Function 
Grade 
Manufacturer 
Concentration 
Amount per 
2mL vial 
Bermekimab 
Antibody 
Active 
Substance 
GMP 
XBiotech USA 
Inc. 
100 mg/mL 
200 mg 
Trehalose 
Dihydrate 
Tonacity 
GMP, 
USP/NF, EP, 
low endotoxin 
Ferro-Pfanstiehl 
(USA) 
60 mg/mL 
120 mg 
Sodium 
Phosphate 
Dibasic 
pH buffering 
capacity 
GMP, EP, USP 
JT Baker (USA) 
12 mg/mL 
24 mg 
Citric Acid 
Monohydrate 
pH buffering 
capacity 
GMP, EP, 
USP, BP, JP 
Fisher (USA) 
2 mg/mL 
4 mg 
Water for 
Injection 
Solvent 
GMP, EP, USP 
Irvine Scientific 
(USA) 
q.s. 
q.s. 
Phosphoric Acid 
pH  
adjustment 
GMP, EP, USP 
JT Baker (USA) 
pH  
adjustment 
pH 
adjustment 


XBIOTECH USA INC.            
 
PROTOCOL 2018-PT044 Version 3.0 
CONFIDENTIAL                                        22 August  2018                                            PAGE 16 of 52 
 
Sodium 
Hydroxide,  
pH  
adjustment 
GMP, EP, USP 
JT Baker (USA) 
pH  
adjustment 
pH 
adjustment 
 
 
2.3 DRUG PRODUCT (BERMEKIMAB 200 MG/ML) DESCRIPTION 
XBiotech’s dosage form is a sterile liquid formulation of 200 mg/mL bermekimab in a stabilizing 
isotonic subcutaneous formulation buffer at pH 6.2-6.5.   The drug product is packaged in pre-filled 
syringes. 
 
The pre-filled syringes used are OMPI EZ-Fill Nexa, 2.25mL 27G ½ needle, or a comparable 
alternative.  The barrel of the syringe is clear glass borosilicate type 1 with AISI 304 stainless 
steel thin wall needle containing 2mL of the formulation and is sealed with West 1-3mL 
Novapure piston (plunger) with Flurotec coating.   
 
Composition Drug Product [200mg/mL]  
Ingredient 
Ingredient 
Function 
Grade 
Manufacturer 
Concentration 
Amount per 2 
mL syringe 
Bermekimab 
Antibody 
Active 
Substance 
GMP 
XBiotech USA 
Inc. 
200 mg/mL 
400 mg 
Trehalose 
Dihydrate 
Tonicity 
GMP, 
USP/NF, 
EP, low 
endotoxin 
Ferro-Pfanstiehl 
(USA) 
60 mg/mL 
120 mg 
Sodium 
Phosphate 
Dibasic 
pH Buffering 
Capacity 
GMP, EP, 
USP 
JT Baker (USA) 
12 mg/mL 
24 mg 
Citric Acid 
Monohydrate 
pH Buffering 
Capacity 
GMP, EP, 
USP, BP, 
JP 
Fisher (USA) 
2 mg/mL 
4 mg 
Water for 
Injection 
Solvent 
GMP, EP, 
USP 
Irvine Scientific 
(USA) 
q.s. 
q.s. 
Phosphoric Acid 
pH adjustment 
GMP, EP, 
USP 
JT Baker (USA) 
pH adjustment 
pH adjustment 
Sodium 
Hydroxide,  
pH adjustment 
GMP, EP, 
USP 
JT Baker (USA) 
pH adjustment 
pH adjustment 
 
2.4 STORAGE 
The recommended storage condition is 2-8°C.  *Product should be warmed to room temperature 
approximately 45-60 minutes prior to injection. 
 
 


XBIOTECH USA INC.            
 
PROTOCOL 2018-PT044 Version 3.0 
CONFIDENTIAL                                        22 August  2018                                            PAGE 17 of 52 
 
2.5 STABILITY 
The drug product is formulated in a buffer in which most of the tonicity comes from trehalose rather 
than salt. Trehalose is an effective stabilizer against oxidation and aggregation, as well as thermal 
and mechanical stress. Citrate was selected as the buffering agent due to its antioxidant properties. 
 
Extensive stability data indicates that the drug product is very stable, even under thermally and 
mechanically stressed conditions. Short excursions to room temperature have shown no negative 
effect on the product. However, the study treatment products are not to be frozen at any time.  The 
100 mg/ml and 200 mg/ml drug product is labeled with a 12-month retest date.  Every lot of both 
the 100/200mg/ml dosage forms is also subjected to ongoing stability analysis per ICH guidelines.  
 
2.6 METHOD OF ADMINISTRATION 
The dose of bermekimab for Group A is 200 mg (2ml of the 100 mg/ml formulation) and for Group 
B is 400 mg (2ml of the 200 mg/ml formulation) administered weekly by subcutaneous injection. 
 
* 45-60 minutes prior to injection, remove the pre-filled syringe from refrigeration and 
allow it to naturally warm to room temperature before injection. Do not heat the 
syringe. 
 
Materials 
Bermekimab pre-filled syringe for injection, warmed to room temperature* 
Sterile alcohol wipes 
Band-aids, along with 2x2 gauze bandages and paper tape 
Latex-free gloves 
 
Injection Site 
Determine Injection site, see illustration below:  
Abdomen, at least 2 inches away from the belly button, is the recommended injection site for 
patients with a body mass index (BMI) below 30.  (This measurement is calculated at Screening.)  
Front Thigh or Upper Arm is the recommended injection site for patients with a BMI of 30 or 
more.   
(Note: avoid areas where the skin is burned, scarred, hardened, inflamed, swollen, or damaged). 


XBIOTECH USA INC.            
 
PROTOCOL 2018-PT044 Version 3.0 
CONFIDENTIAL                                        22 August  2018                                            PAGE 18 of 52 
 
 
Injection 
• 
Put on gloves 
• 
Wipe injection site clean with alcohol pads 
• 
Raise a fold of skin between the thumb and forefinger (see illustration below).  
 
• 
Insert needle as illustrated above 
• 
Inject drug slowly  
• 
Withdraw needle. Place band-aid over injection site if necessary (Note: If bleeding 
occurs, hold pressure on the injection site for 90 seconds or until bleeding stops, and 
then apply gauze bandage secured by tape). 
 
2.7 ORDERING OF STUDY DRUG 
Drug may be ordered from the sponsor as needed. 
 


XBIOTECH USA INC.            
 
PROTOCOL 2018-PT044 Version 3.0 
CONFIDENTIAL                                        22 August  2018                                            PAGE 19 of 52 
 
2.8 POTENTIAL DRUG INTERACTIONS 
There are no known drug interactions with the IL-1 antagonist bermekimab. In controlled trials that 
combined the use of IL-1ra (anakinra), an IL-1 antagonist, together with TNF alpha inhibitors, a 
higher incidence of serious infection was noted. Bermekimab has not been administered 
concomitantly with these agents in clinical trials. However, due to potential risk, it is not 
recommended that bermekimab be used in combination with anti-TNF agents or other IL-1 
antagonists.   
 
2.9 CONCOMITANT MEDICATIONS AND PROCEDURES 
Any treatment (including nutritional supplements) or procedure administered from the time of 
consent to the end-of-study visit (visit 9) is considered concomitant and will be recorded in the case 
report form (CRF). This includes permitted medications ongoing at the time of consent and 
throughout the study. Concomitant procedures are allowed with the exception of those listed in 
section 2.9.1. 
 
2.9.1 Prohibited and Restricted Therapies 
Treatment with the following concomitant medications is prohibited through visit 9: 
• 
Treatment with a live (attenuated) vaccine. 
• 
Treatment with an investigational drug (other than bermekimab). 
• 
Treatment with TCS or TCI 
• 
Treatment with systemic corticosteroids or non-steroidal systemic immunosuppressive 
drugs (eg, cyclosporine, methotrexate, mycophenolate-mofetil, azathioprine, etc.) 
 
Study drug will be discontinued if any of the following are used through visit 9: 
• 
Treatment with a live (attenuated) vaccine 
• 
Treatment with an investigational drug (other than dupilumab) 
• 
Treatment with systemic corticosteroids or non-steroidal systemic immunosuppressive 
drugs (eg, cyclosporine, methotrexate, mycophenolate-mofetil, azathioprine, etc.) 
 
NOTE: If a patient receives treatment with systemic corticosteroids or other systemic 
immunosuppressive drugs (cyclosporine, methotrexate, mycophenolate mofetil, azathioprine, 
etc.), study treatment will be immediately discontinued.  
 


XBIOTECH USA INC.            
 
PROTOCOL 2018-PT044 Version 3.0 
CONFIDENTIAL                                        22 August  2018                                            PAGE 20 of 52 
 
The following concomitant procedures are prohibited during study participation: 
 
• 
Major elective surgical procedures 
• 
Phototherapy 
• 
Tanning in a bed/booth 
 
2.9.2 Permitted Medications and Procedures 
 
Other than the prohibited medications listed in section 5.9.1, treatment with concomitant 
medications is permitted during the study. This includes basic skin care (cleansing and bathing, 
including bleach baths), emollients (required as background treatment), topical anesthetics, 
antihistamines, and topical and systemic anti-infective medications for any duration. 
Medications used to treat chronic disease such as diabetes, hypertension, and asthma are also 
permitted; if there is any question regarding whether a concomitant medication may be used 
during the study, the study site should contact the medical monitor. 
 
3.  STUDY DESIGN AND OBJECTIVES 
 
Phase 2, open label, dose escalation study of two dose cohorts of bermekimab in patients with 
moderate to severe atopic dermatitis. The study is multicenter, and will consist of two dose levels:  
Bermekimab administered subcutaneously at a dose of 200 mg weekly (4 doses) and bermekimab 
administered subcutaneously at a dose of 400 mg weekly (8 doses).  Patients taking the 200mg dose 
will be followed for 5 weeks (6 visits, day 35 +/-2), and patients taking the 400mg dose will be 
followed for 8 weeks (9 visits, day 56 +/-2) to allow for assessment of safety and preliminary 
efficacy. 
 
Dose escalation details can be found in Section 5.3.  
 
The protocol of the study will be approved by the Institutional Review Board (IRB) or the Ethics 
Committee (EC) of the participating study sites. Depending on the participating countries, both 
local and central IRB/EC approvals will be granted. The study will be registered at 
www.clinicaltrials.gov before the enrollment of the first patient.  The trial will be conducted in 
compliance with the protocol, GCP, and all applicable regulatory requirements. 
 
 


XBIOTECH USA INC.            
 
PROTOCOL 2018-PT044 Version 3.0 
CONFIDENTIAL                                        22 August  2018                                            PAGE 21 of 52 
 
3.1 STUDY ENDPOINTS 
 
Primary Endpoint: 
• 
Safety and Tolerability 
 
Secondary Endpoints: 
• 
Change in Eczema Area and Severity Index Score (EASI) from baseline to visit 8    
EASI score will assess severity and extent of AD with respect to erythema, 
excoriation, infiltration and lichenification at 4 anatomic sites of the body: lower 
and upper extremities, trunk and head. The total EASI score shall be in a range 
(from 0 to 72 points (from no disease to maximum disease severity, respectively). 
• 
Patients (%) achieving Investigator's Global Assessment (IGA) Response (0 or 1) at Visit 
8 
IGA assesses disease severity and clinical response using a 5-point scale: 0 = clear; 
1 = almost clear; 2 = mild; 3 = moderate; 4 = severe. The score is determined by 
ranking the extent of erythema and papulation/infiltration. A clinical response to 
therapy will be an IGA score of 0 (clear) or 1 (almost clear).  Patients receiving 
more than one treatment with additional medication to treat AD exacerbation 
during the study or missing IGA scores at Visit 8 will be treated as non-responders. 
• 
Patients (%) achieving ≥2 IGA Score Reduction at Visit 8 
• 
Pharmacokinetics (PK) Assessment  
An enzyme-linked immunosorbent assay (ELISA) has been developed to 
specifically measure bermekimab levels in human plasma. Blood will be drawn 
into a single 6 ml Na-Heparin collection tube at each PK collection time point 
(sample collection is pre-dose at visit 1, visit 3, visit 5, and visit 8). These samples 
will be collected per the study lab manual and immediately shipped to the Sponsor 
for PK analysis. The PK samples will also be used to test for the presence of 
antibodies against bermekimab. 
• 
Change (%) for peak weekly averaged pruritus numerical rating scores (NRS) from 
baseline to visit 8 
1. The NRS rating system captures the intensity of patient’s itch and pain over a 24-hour 
period. The following question will be presented to patients: “how would a participant rate 
his or her itch at the worst moment and on average during the previous 24 hours (scale 0 - 
10 [0 = no itch; 10 = worst possible itch])?” and “how would you rate your pain on average 
during the previous 24 hours [0 = no pain; 10 = severe pain])? 


XBIOTECH USA INC.            
 
PROTOCOL 2018-PT044 Version 3.0 
CONFIDENTIAL                                        22 August  2018                                            PAGE 22 of 52 
 
• 
Change in weekly averaged peak NRS from baseline to visit 8  
• 
Change in SCORing Atopic Dermatitis (SCORAD) score from baseline to visit 8  
SCORAD was developed by the European Task Force on Atopic Dermatitis 
(Severity scoring of atopic dermatitis: the SCORAD index) as a measure of 
disease severity in AD. It includes assessment of the eczema in addition to patient 
reported symptoms. Total score ranges from 0 to 103 (no disease to most severe 
disease, respectively). 
• 
Patients (%) achieving 50% or greater reduction in EASI Score from baseline to Visit 8 
• 
Patients (%) achieving 50% or greater reduction in SCORAD Score to Visit 8  
• 
Change (%) in Patient Oriented Eczema Measure (POEM) Scores from baseline to Visit 8 
POEM is a 7-item is a patient reported quality of life outcome measure based on a 
questionnaire to determine disease symptoms, including bleeding, cracking, 
dryness, flaking, itching, sleep loss and weeping. The scoring range is from 0 to 
28 (no disease to most severe disease, respectively). 
• 
Changes in Global Individual Signs Score (GISS) from baseline to visit 8 
• 
Change from baseline to visit 8 in Hospital Anxiety Depression Scale (HADS) 
• 
Change (%) from pre- and post- injection of Visit 1 Questionnaire for pruritus, pain and 
erythema 
 
 
 
 
GISS assesses AD lesions for erythema, excoriations, lichenification and 
edema/papulation. Each component will be rated on a global basis (over the entire 
body surface rather than by region) using a 4-point scale (0=none, 1=mild, 
2=moderate and 3=severe) according to the EASI grading severity. Total score will 
range from 0 to 12 (no disease to most severe disease, respectively). 
• 
Change from baseline to visit 8 in Dermatology Life Quality Index (DLQI) 


XBIOTECH USA INC.            
 
PROTOCOL 2018-PT044 Version 3.0 
CONFIDENTIAL                                        22 August  2018                                            PAGE 23 of 52 
 
4.  ELIGIBILITY CRITERIA 
 
4.1 INCLUSION CRITERIA 
No waivers/exemptions will be granted for protocol inclusion/exclusion criteria. 
 
Subjects are included in the study if they meet all of the following criteria: 
• 
Documented recent history (within 6 months before the screening visit) of inadequate response 
to treatment with topical medications or for whom topical treatments are otherwise medically 
inadvisable or undesired 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
• 
Written informed consent provided by the patient 
• 
Age ≥18 years 
• 
Chronic Atopic Dermatitis present for at least 3 years 
• 
Disease is not responsive to topical medications, or for whom topical treatments are not 
indicated or desired 
• 
Willing and able to comply with all clinic visits and study-related procedure 
• 
EASI score ≥16 at screening and baseline visits 
• 
IGA score ≥3 at screening and baseline visits 
• 
≥10% body surface area (BSA) of AD involvement at screening and baseline visits 


XBIOTECH USA INC.            
 
PROTOCOL 2018-PT044 Version 3.0 
CONFIDENTIAL                                        22 August  2018                                            PAGE 24 of 52 
 
4.2 EXCLUSION CRITERIA 
Subjects will be excluded from the study if they meet any of the following criteria: 
 
• 
Treatment with an investigational drug within 8 weeks of baseline visit 
• 
Having received the following treatments within 4 weeks before the baseline visit, or any 
condition that, in the opinion of the investigator, is likely to require such treatment(s) during 
the first 4 weeks of study treatment:   
a. Immunosuppressive/immunomodulating drugs (eg, systemic corticosteroids, 
cyclosporine, 
mycophenolate-mofetil, 
IFN-γ, 
Janus 
kinase 
inhibitors, 
azathioprine, methotrexate, etc.) 
b. Phototherapy for AD 
• 
Treatment with topical corticosteroids (TCS) or topical calcineurin inhibitors (TCI) within 1 
week before the baseline visit 
• 
Initiation of treatment during the screening period with prescription moisturizers or 
moisturizers containing additives such as ceramide, hyaluronic acid, urea, or filaggrin 
degradation products during the screening period (patients may continue using stable doses of 
such moisturizers if initiated before the screening visit) 
• 
Regular use (more than 2 visits per week) of a tanning booth/parlor within 4 weeks of the 
screening visit 
• 
History of severe allergic or anaphylactic reactions to monoclonal antibodies 
• 
Administration of any live (attenuated) vaccine within 4 weeks prior to the baseline 
• 
Any history of dysplasia or history of malignancy (including lymphoma and leukemia) other 
than a successfully treated non-metastatic cutaneous squamous cell carcinoma, basal cell 
carcinoma or localized carcinoma in situ of the cervix  
• 
Active chronic or acute infection requiring treatment with systemic antibiotics, antivirals, 
antiparasitics, antiprotozoals, or antifungals within 2 weeks before the baseline visit, or 
superficial skin infections within 1 week before the baseline visit. NOTE: patients may be 
rescreened after infection resolves 
• 
Known or suspected history of immunosuppression, including history of invasive 
opportunistic 
infections 
(eg, 
tuberculosis 
[TB], 
histoplasmosis, 
listeriosis, 
coccidioidomycosis, pneumocystosis, aspergillosis) despite infection resolution: or unusually 
frequent, recurrent, or prolonged infections, per investigator judgment 
• 
History of human immunodeficiency virus (HIV) infection or positive HIV serology at 
screening 
• 
Positive with hepatitis B surface antigen (HBsAg) or hepatitis C antibody at the screening visit 
• 
Presence of skin comorbidities that may interfere with study assessments 


XBIOTECH USA INC.            
 
PROTOCOL 2018-PT044 Version 3.0 
CONFIDENTIAL                                        22 August  2018                                            PAGE 25 of 52 
 
• 
Where relevant, women unwilling to use adequate birth control 
 
 
• 
Severe concomitant illness(es) that, in the investigator’s judgment, would adversely affect the 
patient’s participation in the study. Examples include, but are not limited to, patients with short 
life expectancy, patients with uncontrolled diabetes (HbA1c ≥ 9%),  patients with 
cardiovascular conditions (eg, stage III or IV cardiac failure according to the New York Heart 
Association classification), severe renal conditions (eg, patients on dialysis), hepato-biliary 
conditions (eg, Child-Pugh class B or C), neurological conditions (eg, demyelinating diseases), 
active major autoimmune diseases (eg, lupus, inflammatory bowel disease, rheumatoid 
arthritis, etc.), other severe endocrinological, gastrointestinal, metabolic, pulmonary or 
lymphatic diseases. The specific justification for patients excluded under this criterion will be 
noted in study documents (chart notes, case report forms [CRFs], etc.) 
• 
Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed 
during the study 


XBIOTECH USA INC.            
 
PROTOCOL 2018-PT044 Version 3.0 
CONFIDENTIAL                                        22 August  2018                                            PAGE 26 of 52 
 
5.   TREATMENT PLAN 
 
5.1 STUDY PROCEDURES 
Screening 
 
The screening period begins once the informed consent is signed (Max 14 days).   
 Informed Consent 
• 
Demographics 
• 
Medical History 
• 
Concomitant Medications/Treatments 
• 
Physical Examination  
• 
Vital Signs (blood pressure, pulse, oxygen saturation, respiratory rate and body 
temperature) 
• 
Height  
• 
Weight 
• 
Body Mass Index (BMI) [BMI= weight (kg)/height (m2)] 
• 
EASI 
• 
IGA 
• 
SCORAD 
• 
Blood Draw, 21mL: 
o Chemistry panel: Albumin, Alkaline Phosphatase, ALT, AST, GGT, 
Bicarbonate (CO2) Calcium, Chloride,   Creatinine, Glucose, Potassium, 
Sodium, Total Bilirubin, Total Protein, Urea Nitrogen, 8.5 mL blood 
o Hematology Panel: Complete Blood Count (CBC) with differential and 
platelets, 4.0 mL blood 
o Infectious disease screening: HIV antibody, Hepatitis C antibody, 
Hepatitis B panel (HBsAg, anti-HBc, anti-HBs), and interferon gamma 
release assay (IGRA), 8.5 mL blood 
o Serum pregnancy test for WOCBP, 8.5 mL blood 
• 
Pruritus/Pain NRS:  the baseline level of itching and pain will be recorded.  Patients will 
be given a study diary that has the NRS (0-10 scale) for days 0 to 35.  The patient will be 
instructed to complete the scale daily (three questions, each on a 0-10 scale).  The patient 
should bring this diary to all subsequent visits for review by the site staff. 
 
Visit 1 (Day 0) 
 At least 45 minutes before injection:  When using pre-filled syringes, remove syringe from 
refrigeration and lay flat; allow to warm to room temperature.  Do not heat 
Pre-injection 
o Concomitant medications/treatments 
o Urinalysis 
o Electrocardiogram (ECG) (patient should be supine for at least 5 minutes prior to 
performating ECG) 
o DLQI 
o Urine pregnancy 
o EASI 
o IGA 


XBIOTECH USA INC.            
 
PROTOCOL 2018-PT044 Version 3.0 
CONFIDENTIAL                                        22 August  2018                                            PAGE 27 of 52 
 
o HADS 
o Pruritus/Pain NRS:  data from patient diary to be recorded at this time if available 
o SCORAD 
o POEM 
o GISS 
o Blood draw: 
 
PK and Biomarker Analysis, 6mL 
o Visit 1 Questionnaire, Part 1: Pruritus, Pain and Erythema 
o Vital signs (blood pressure, pulse, oxygen saturation, respiratory rate and body 
temperature) 
 
Bermekimab subcutaneous injection in accordance with injection site determined by BMI at 
Screening 
  
Post bermekimab subcutaneous injection 
 1 hour monitoring post-injection 
o Injection reaction   
o Vital signs (blood pressure, pulse, oxygen saturation, respiratory rate and body 
temperature) one hour post injection (70 +/- 10 minutes) 
o Visit 1 Questionnaire, Part 2: Pruritus, Pain and Erythema—data from this form 
must be recorded one hour post-injection (70 +/- 10 minutes) 
 Adverse event monitoring 
 
Visit 2 (Day 7 +/-2) 
 At least 45 minutes before injection:  When using pre-filled syringes, remove syringe from 
refrigeration and lay flat; allow to warm to room temperature.  Do not heat 
Pre-injection 
o Concomitant medications/treatments 
o DLQI 
o Urine pregnancy 
o EASI 
o IGA 
o HADS 
o Pruritus/Pain NRS:  data from patient diary to be recorded at this time if available 
o SCORAD 
o POEM 
o GISS 
o Vital signs (blood pressure, pulse, oxygen saturation, respiratory rate and body 
temperature) 
 
Bermekimab subcutaneous injection in accordance with injection site determined by BMI at 
Screening 
 
Post bermekimab subcutaneous injection 
 1 hour monitoring post-injection 
o Injection reaction   
o Vital signs (blood pressure, pulse, oxygen saturation, respiratory rate and body 
temperature) one hour post injection (70 +/- 10 minutes) 
 
Adverse event monitoring 


XBIOTECH USA INC.            
 
PROTOCOL 2018-PT044 Version 3.0 
CONFIDENTIAL                                        22 August  2018                                            PAGE 28 of 52 
 
Visit 3 (Day 14 +/-2) 
 At least 45 minutes before injection:  When using pre-filled syringes, remove syringe from 
refrigeration and lay flat; allow to warm to room temperature.  Do not heat 
Pre-injection 
o Concomitant medications/treatments 
o DLQI 
o Urine pregnancy 
o EASI 
o IGA 
o HADS 
o Pruritus/Pain NRS:  data from patient diary to be recorded at this time if available 
o SCORAD 
o POEM 
o GISS 
o Blood draw: 
 
chemistry and hematology, 12.5mL 
 
PK and Biomarker Analysis, 6mL 
o Vital signs (blood pressure, pulse, oxygen saturation, respiratory rate and body 
temperature) 
 
Bermekimab subcutaneous injection in accordance with injection site determined by BMI at 
Screening 
 
Post bermekimab subcutaneous injection 
 1 hour monitoring post-injection 
o Vital signs (blood pressure, pulse, oxygen saturation, respiratory rate and body 
temperature) one hour post injection (70 +/- 10 minutes) 
 
Adverse event monitoring 
 
Visit 4 (Day 21 +/-2) 
 At least 45 minutes before injection:  When using pre-filled syringes, remove syringe from 
refrigeration and lay flat; allow to warm to room temperature.  Do not heat 
Pre-injection 
o Concomitant medications/treatments 
o Urinalysis 
o DLQI 
o Urine pregnancy 
o EASI 
o IGA 
o HADS 
o Pruritus/Pain NRS:  data from patient diary to be recorded at this time if available 
o SCORAD 
o POEM 
o GISS 
o Vital signs (blood pressure, pulse, oxygen saturation, respiratory rate and body 
temperature) 
 


XBIOTECH USA INC.            
 
PROTOCOL 2018-PT044 Version 3.0 
CONFIDENTIAL                                        22 August  2018                                            PAGE 29 of 52 
 
Bermekimab subcutaneous injection in accordance with injection site determined by BMI at 
Screening 
 
Post bermekimab subcutaneous injection 
 1 hour monitoring post-injection 
o Injection reaction   
o Vital signs (blood pressure, pulse, oxygen saturation, respiratory rate and body 
temperature) one hour post injection (70 +/- 10 minutes) 
 Adverse event monitoring 
 
Visit 5 (day 28 +/-2) 
 At least 45 minutes before injection:  When using pre-filled syringes, remove syringe from 
refrigeration and lay flat; allow to warm to room temperature.  Do not heat 
Pre-injection 
o Concomitant medications/treatments 
o Physical Examination 
o DLQI 
o Urine pregnancy 
o EASI 
o IGA 
o HADS 
o Pruritus/Pain NRS:  data from patient diary to be recorded at this time if available 
o SCORAD 
o POEM 
o GISS 
o Blood draw: 
 
chemistry and hematology, 12.5mL 
 
PK and Biomarker Analysis, 6mL 
o Vital signs (blood pressure, pulse, oxygen saturation, respiratory rate and body 
temperature) 
 
Bermekimab subcutaneous injection in accordance with injection site determined by BMI at 
Screening 
 
Post bermekimab subcutaneous injection 
 1 hour monitoring post-injection 
o Injection reaction   
o Vital signs (blood pressure, pulse, oxygen saturation, respiratory rate and body 
temperature) one hour post injection (70 +/- 10 minutes) 
 
Adverse event monitoring 
 
Visit 6 (day 35 +/-2) 
 At least 45 minutes before injection:  When using pre-filled syringes, remove syringe from 
refrigeration and lay flat; allow to warm to room temperature.  Do not heat 
Pre-injection 
o Concomitant medications/treatments 


XBIOTECH USA INC.            
 
PROTOCOL 2018-PT044 Version 3.0 
CONFIDENTIAL                                        22 August  2018                                            PAGE 30 of 52 
 
o DLQI 
o Urine pregnancy 
o EASI 
o IGA 
o HADS 
o Pruritus/Pain NRS:  data from patient diary to be recorded at this time if available 
o SCORAD 
o POEM 
o GISS 
o Vital signs (blood pressure, pulse, oxygen saturation, respiratory rate and body 
temperature) 
 
Bermekimab subcutaneous injection in accordance with injection site determined by BMI at 
Screening 
 
Post bermekimab subcutaneous injection 
 1 hour monitoring post-injection 
o Injection reaction   
o Vital signs (blood pressure, pulse, oxygen saturation, respiratory rate and body 
temperature) one hour post injection (70 +/- 10 minutes) 
 Adverse event monitoring 
 
Visit 7 (day 42 +/-2) 
 At least 45 minutes before injection:  When using pre-filled syringes, remove syringe from 
refrigeration and lay flat; allow to warm to room temperature.  Do not heat 
Pre-injection 
o Concomitant medications/treatments 
o DLQI 
o Urine pregnancy 
o EASI 
o IGA 
o HADS 
o Pruritus/Pain NRS:  data from patient diary to be recorded at this time if available 
o SCORAD 
o POEM 
o GISS 
o Vital signs (blood pressure, pulse, oxygen saturation, respiratory rate and body 
temperature) 
 
Bermekimab subcutaneous injection in accordance with injection site determined by BMI at 
Screening 
 
Post bermekimab subcutaneous injection 
 1 hour monitoring post-injection 
o Injection reaction   
o Vital signs (blood pressure, pulse, oxygen saturation, respiratory rate and body 
temperature) one hour post injection (70 +/- 10 minutes) 
 Adverse event monitoring 


XBIOTECH USA INC.            
 
PROTOCOL 2018-PT044 Version 3.0 
CONFIDENTIAL                                        22 August  2018                                            PAGE 31 of 52 
 
Visit 8 (day 49 +/- 2) 
 At least 45 minutes before injection:  When using pre-filled syringes, remove syringe from 
refrigeration and lay flat; allow to warm to room temperature.  Do not heat 
Pre-injection 
o Concomitant medications/treatments 
o Urinalysis 
o Electrocardiogram (ECG) (patient should be supine for at least 5 minutes prior to 
performating ECG) 
o Physical Examination 
o DLQI 
o Urine pregnancy 
o EASI 
o IGA 
o HADS 
o Pruritus/Pain NRS:  data from patient diary to be recorded at this time if available 
o SCORAD 
o POEM 
o GISS 
o Blood draw: 
 
chemistry and hematology, 12.5mL 
 
PK and Biomarker Analysis, 6mL 
o Vital signs (blood pressure, pulse, oxygen saturation, respiratory rate and body 
temperature) 
 
Bermekimab subcutaneous injection in accordance with injection site determined by BMI at 
Screening 
 
Post bermekimab subcutaneous injection 
 1 hour monitoring post-injection 
o Injection reaction   
o Vital signs (blood pressure, pulse, oxygen saturation, respiratory rate and body 
temperature) one hour post injection (70 +/- 10 minutes) 
 
Adverse event monitoring 
 
Visit 9 (56 +/- 2) 
 
 Concomitant medications/treatments 
 DLQI 
 Physical Examination 
 EASI 
 IGA 
 HADS 
 Pruritus/Pain NRS:  patient diary to be retained and data to be recorded 
 SCORAD 
 POEM 
 GISS 
 Vital signs (blood pressure, pulse, oxygen saturation, respiratory rate and body 
temperature) 
 Adverse Event Monitoring 


XBIOTECH USA INC.            
 
PROTOCOL 2018-PT044 Version 3.0 
CONFIDENTIAL                                        22 August  2018                                            PAGE 32 of 52 
 
 
5.2 STUDY CALENDAR  
 
Visit 
Screen 
1 
2 
3 
4 
5 
6 
7 
8 
9 
Study Day 
 
0 
7 ±2 
14 ± 2 
21± 2 
28 ± 2 
35 ± 2 
42 ± 2 
49 ± 2 
56 ± 2 
Informed Consent 
x 
 
 
 
 
 
 
 
 
 
Demography, Height, Weightf 
x 
 
 
 
 
 
 
 
 
 
Medical History 
x 
 
 
 
 
 
 
 
 
 
Infectious Disease Panel✢ 
x 
 
 
 
 
 
 
 
 
 
IGRAe 
x 
 
 
 
 
 
 
 
 
 
Serum Pregnancy 
x 
 
 
 
 
 
 
 
 
 
Physical Examination 
x 
 
 
 
 
x 
 
 
x 
x 
Urinalysis▲  
 
x 
 
 
x 
 
 
 
x 
 
Electrocardiogram (ECG)£ 
 
x 
 
 
 
 
 
 
x 
 
Visit 1 Questionnaire✦ 
 
x 
 
 
 
 
 
 
 
 
Vital Signs+ 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
Urine Pregnancy 
 
x 
x 
x 
x 
x 
x 
x 
x 
 
Blood Draw 
  xab 
 xc 
 
   xabc 
 
   xabc 
 
 
  xabc 
 
Bermekimab Injection❖ 
 
x 
x 
x 
x 
x 
x 
x 
x 
 
EASI   
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
IGA 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
SCORAD 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
DLQI 
 
x 
x 
x 
x 
x 
x 
x 
x 
x 
Pruritus/pain NRSd 
 
x 
x 
x 
x 
x 
x 
x 
x 
x 
POEM 
 
x 
x 
x 
x 
x 
x 
x 
x 
x 
GISS 
 
x 
x 
x 
x 
x 
x 
x 
x 
x 
HADS 
 
x 
x 
x 
x 
x 
x 
x 
x 
x 
Adverse Events 
 
x 
x 
x 
x 
x 
x 
x 
x 
x 
Concomitant 
Meds/Treatments* 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
 
a  Chemistry Panel including: Albumin, Alkaline Phosphatase, ALT, AST, GGT, Bicarbonate (CO2) Calcium, 
Chloride, Creatinine, Glucose, Potassium, Sodium, Total Bilirubin, Total Protein, Urea Nitrogen 
b Hematology Panel including: Complete whole blood (WBC, HgB, Platelet, differential) 
c Blood draw for PK and Biomarker analysis  
d Data from patient diary for the previous 7 days to be recorded at this time. 
e Interferon gamma release assay  
f BMI will be calculated at this visit using height and weight  
✢HIV antibody, Hepatitis C antibody, Hepatitis B panel (HBsAg, anti-HBc, anti-HBs) , and interferon gamma 
release assay (IGRA)   
▲ Urinalysis will assess pH, protein, glucose, and blood cells 
£ A standard 12-lead ECG will be performed. The ECG strips and/ or reports will be retained with the source 
documentation.  
❖  Each bermekimab injection will be followed by 1 hour monitoring for injection site reaction and vital signs 1 
hour   post injection (70+/- 10 minutes) 
+ Vital signs include blood pressure, pulse, oxygen saturation, respiratory rate and body temperature  
✦  Assessment of patients Pruritus, Pain and Erythema will be recorded twice [once pre-injection, once post-
injection of bermekimab] during visit 1. 
* Concomitant medications within 30 days before screening until 7 days after the last administration of the study 
drug must be recorded for the purpose of drug-drug and drug-disease interaction evaluation and signal detection. 
 
 


XBIOTECH USA INC.            
 
PROTOCOL 2018-PT044 Version 3.0 
CONFIDENTIAL                                        22 August  2018                                            PAGE 33 of 52 
 
BMI:  Body Mass Index [BMI= weight (kg)/height (m2)] 
IGRA: Interferon Gamma Release Assay 
DLQI: Dermatology Life Quality Index 
EASI: Eczema Area and Severity Index Score 
IGA: Investigator's Global Assessment 
NRS: Numerical Rating Scores 
SCORAD: Severity Scoring of Atopic Dermatitis 
POEM: Patient Oriented Eczema Measure 
GISS: Global Individual Signs Score 
HADS: Hospital Anxiety Depression Scale 
 
5.3 DOSE ESCALATION RULES 
The National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) 
v4.03 will be used to grade the severity of adverse events.   
 
Any AE (with the exception of worsening AD symptoms or injection site reactions) of 
grade 2 or higher that is probably or definitely related to study drug must be reported to the 
sponsor within 24 hours of learning of the event.   
 
Any grade 3 or greater injection site reaction must be reported to the sponsor within 24 
hours of learning of the event. 
 
If three or more probably or definitely related grade 2 or greater AEs, and/or three or more 
grade 3 or greater injection site reactions occur in either group, dosing will be stopped for 
safety assessment.  
 
5.4 RESCUE TREATMENT(S) 
If medically necessary (ie, to control intolerable AD symptoms), rescue treatment for AD may be 
provided to study patients at the discretion of the investigator. For the purpose of efficacy analysis, 
patients who receive rescue treatment during the study treatment period will be considered 
treatment failures, but they will continue study treatment if rescue consisted of topical medications. 
Topical calcineurin inhibitors may be used for rescue, but should be reserved for problem areas 
only, eg, face, neck, intertriginous and genital areas, etc. If possible, investigators should attempt 
to limit the first step of rescue therapy to topical medications, and escalate to systemic medications 
only for patients who do not respond adequately after at least 7 days of topical treatment. If a patient 
receives 
rescue 
treatment 
with 
systemic 
corticosteroids 
or 
non-steroidal 
systemic 
The sponsor will review safety data for all patients after the last patient in Group A has completed 
the week 4 visit or discontinued for any reason other than DLT.  The sponsor will initiate escalation 
to the Group B dosing cohort after confirmation that no safety signals are identified and no study 
stopping rules have been met. 
 


XBIOTECH USA INC.            
 
PROTOCOL 2018-PT044 Version 3.0 
CONFIDENTIAL                                        22 August  2018                                            PAGE 34 of 52 
 
immunosuppressive drugs (cyclosporine, methotrexate, mycophenolate-mofetil, azathioprine, etc.) 
study treatment will be immediately discontinued. Investigators should make every attempt to 
conduct efficacy and safety assessments (eg, disease severity scores, safety labs) immediately 
before administering any rescue treatment.  
 
 
5.5 DISCONTINUATION OF THERAPY 
If a patient is discontinued from study, the reason for discontinuation must be clearly documented 
in the source documentation and the EDC. 
 
Study therapy for a given patient MUST immediately be discontinued for any the following 
reasons:  
 
Withdrawal of informed consent (subject’s decision to withdraw for any reason)  
 
Any clinical adverse event, laboratory abnormality, inter-current illness, or clinical progression 
of disease which, in the opinion of the Principal Investigator, indicates that continued 
participation in the study is not in the best interest of the subject  
 
Pregnancy  
 
Termination of the study by the sponsor 
 
Imprisonment or the compulsory detention for treatment of either a psychiatric or physical (e.g., 
infectious disease) illness  
 
Any Grade 2 or greater adverse event (with the exception of worsening AD symptoms or 
injection site reactions) that is determined to be probably or definitely related to study drug 
administration. 
 
Any Grade 3 or greater injection site reaction 
 
Certain rescue treatments as specified in section 5.4 
 
 
5.6 TRIAL STOPPING RULES 
Enrollment of any further patients for the trial will be suspended for the following events: 
• The death of a subject at any time during the trial that is deemed to be probably or 
definitely related to the administration of MABp1 
• The occurrence of 2 or more serious adverse events occurring cumulatively and 
irrespective of dose cohort, that are probably or definitely related to the 
administration of MABp1 


XBIOTECH USA INC.            
 
PROTOCOL 2018-PT044 Version 3.0 
CONFIDENTIAL                                        22 August  2018                                            PAGE 35 of 52 
 
• Any significant safety finding assessed as probably or definitely related to MABp1 
that in the opinion of the investigator warrants stopping the trial for additional 
assessment of safety. 
 
6.  CORRELATIVE STUDIES 
 
6.1 PHARMACOKINETICS (PK) SAMPLE COLLECTION 
An enzyme-linked immunosorbent assay (ELISA) has been developed to specifically measure 
bermekimab levels in human plasma. Blood will be drawn into a single 6 ml collection tube at each 
PK collection time point (pre-dose sample collection at visit 1, visit 3, visit 5,  and visit 8). These 
samples will be collected per the study lab manual and immediately shipped to the Sponsor for PK 
analysis. The PK samples will also be used to test for the presence of antibodies against 
bermekimab and biomarker analysis.   
 
7.  ASSESSMENT OF SAFETY 
 
Safety will be assessed by monitoring adverse events, vital signs, physical examinations, ECG and 
clinical laboratory measurements. All subjects who have received at least one dose of bermekimab 
will be included in the safety analysis.  Adverse events will be monitored from Visit 1 (post-
infusion) to Visit 9.  Any serious adverse events or grade 2 or greater probably or definitely related 
events will be followed until resolution. 
 
Study drug will be administered under close observation in a facility equipped to handle 
anaphylaxis. Subjects must be closely monitored until at least 1 hour following the administration 
of the antibody or 1 hour after their vital signs have stabilized.     
 
Any AE (with the exception of worsening AD symptoms or injection site reactions) of grade 2 or 
higher must be reported to the sponsor within 24 hours of learning of the event.  Any grade 3 or 
greater injection site reaction must be reported to the sponsor within 24 hours of learning of the 
event. 
 
 
 
 


XBIOTECH USA INC.            
 
PROTOCOL 2018-PT044 Version 3.0 
CONFIDENTIAL                                        22 August  2018                                            PAGE 36 of 52 
 
8.  STUDY VARIABLES 
 
8.1 DEMOGRAPHIC AND DISEASE CHARACTERISTICS 
Demographic characteristics will include standard demography (age, sex, race, weight, and BMI), 
medical history, medication history, and prior biologic use for each patient.  Characteristics of the 
patient’s atopic dermatitis, including duration of disease, baseline EASI score (including individual 
signs score), baseline Investigator’s Global Assessment, baseline body surface area involvement, 
baseline pruritus numerical rating score, baseline SCORAD score, baseline patient oriented eczema 
measure, baseline DLQI, and baseline HADS score, will be collected.  Baseline is defined as the 
visit 1 pre-injection assessment. 
 
8.2 STUDY ENDPOINT DEFINITIONS 
Eczema Area and Severity Index 
The EASI is a validated measure used in clinical practice and clinical trials to assess the severity 
and extent of AD. Four AD disease characteristics will be assessed for severity by the investigator 
or designee on a scale of “0” (absent) through “3” (severe). In addition, the area of AD involvement 
will be assessed as a percentage by body area of head, trunk, arms, and legs and converted to a 
score of 0 to 6.   
Pharmacokinetic Assessment 
An enzyme-linked immunosorbent assay (ELISA) has been developed to specifically measure 
bermekimab levels in human plasma. Blood will be drawn into a single 6 ml Na-Heparin collection 
tube at each PK collection time point (sample collection is pre-dose at visit 1, visit 3, visit 5, and 
visit 8). These samples will be collected per the study lab manual and immediately shipped to the 
Sponsor for PK analysis. The PK samples will also be used to test for the presence of antibodies 
against bermekimab. 
 
Investigator’s Global Assessment 
The IGA is an assessment scale used in clinical studies to determine severity of AD and clinical 
response to treatment based on a 5-point scale ranging from 0 (clear) to 4 (severe).   
 
Global Individual Signs Score 
Individual components of the AD lesions (erythema, edema/papulation, excoriations, and 
lichenification) will be rated globally (ie, each assessed for the whole body, not by anatomical 
region) on a 4-point scale (from 0=none to 3=severe) using the EASI severity grading criteria. 


XBIOTECH USA INC.            
 
PROTOCOL 2018-PT044 Version 3.0 
CONFIDENTIAL                                        22 August  2018                                            PAGE 37 of 52 
 
SCORing Atopic Dermatitis 
The SCORAD is a validated tool used in clinical research and clinical practice that was developed 
to standardize the evaluation of the extent and severity of AD.  There are 3 components to the 
assessment: A = extent or affected body surface area, B = intensity, and C = subjective symptoms. 
The extent of AD is assessed as a percentage of each defined body area and reported as the sum of 
all areas, with a maximum score of 100% (assigned as “A” in the overall SCORAD calculation). 
The intensity of 6 specific symptoms of AD (redness, swelling, oozing/crusting, excoriation, skin 
thickening/ lichenification, dryness) is assessed using the following scale: none (0), mild (1), 
moderate (2), or severe (3) (for a maximum of 18 total points, assigned as “B” in the overall 
SCORAD calculation). Subjective assessment of itch and sleeplessness is recorded for each 
symptom by the patient or relative on a VAS, where 0 is no itch (or sleeplessness) and 10 is the 
worst imaginable itch (or sleeplessness), with a maximum possible score of 20. This parameter is 
assigned as “C” in the overall SCORAD calculation. The SCORAD is calculated as: A/5 + 7B/2 + 
C where the maximum is 103.   
 
Patient Assessment of Pruritus and Pain 
The NRS is a simple assessment tool that patients will use to report the intensity of their pruritus 
(itch) and pain during a daily recall period using a study diary. Patients will be asked to complete 
the following questions: 
• 
For average itch intensity: “On a scale of 0 to 10, with 0 being ‘no itch’ and 10 being the 
‘worst itch imaginable’, how would you rate your itch on average during the previous 24 
hours?” 
• 
For maximum itch intensity: “On a scale of 0 to 10, with 0 being ‘no itch’ and 10 being the 
‘worst itch imaginable’, how would you rate your itch at the worst moment during the 
previous 24 hours?” 
• 
For pain intensity: “On a scale of 0 to 10, with 0 being ‘no pain’ and 10 being the ‘most 
severe pain’, how would you rate your pain on average during the previous 24 hours?” 
Patients will be instructed to record their NRS score daily from day 0 to day 56 (+/-2). Sites will 
be expected to review the diary at each visit and enter the data from the previous 7 days. 
 
Visit 1 Questionnaire for Pruritus, Pain and Erythema 
The following questions assess the intensity of pruritus (itch) and pain experienced by the patient 
before and after the injection of bermekimab during visit 1.  The patient will answer the following 
questions: 


XBIOTECH USA INC.            
 
PROTOCOL 2018-PT044 Version 3.0 
CONFIDENTIAL                                        22 August  2018                                            PAGE 38 of 52 
 
1. On a scale of 0 to 10, what is the current intensity of itch, with 0 being ‘no itch’ 
and 10 being the ‘worst itch imaginable’. 
2. On a scale of 0 to 10, what is the current intensity of pain, with 0 being ‘no pain’ 
and 10 being ‘severe pain’. 
The Investigator will assess the patient’s Erythema and complete the following on the Visit 1 
Questionnaire: 
3. What is the current status of the patient’s erythema overall? 
a. None◻   Mild ◻ Moderate ◻  Severe ◻ 
b. Please describe area(s) and degree(s) of the patient’s erythema in detail and if 
applicable any post-injection changes observed.  
 
The Visit 1 Questionnaire will be performed twice:  
1. Visit 1, pre-injection of bermekimab;   
2. Visit 1, sixty minutes post-injection of bermekimab. 
 
Patient Oriented Eczema Measure 
The POEM is a 7-item, validated questionnaire used in clinical practice and clinical trials to assess 
disease symptoms in children and adults. The format is a response to 7 items (dryness, itching, 
flaking, cracking, sleep loss, bleeding, and weeping) based on frequency during the past week (ie, 
0 = no days, 1 = 1 to 2 days, 2 = 3 to 4 days, 3 = 5 to 6 days, and 4 = every day) with a scoring 
system of 0 to 28; the total score reflects disease-related morbidity.   
Hospital Anxiety and Depression Scale 
The HADS is an instrument for screening anxiety and depression in non-psychiatric populations; 
repeated administration also provides information about changes to a patient’s emotional state. The 
HADS consists of 14 items, 7 each for anxiety and depression symptoms; possible scores range 
from 0 to 21 for each subscale. The following cut-off scores are recommended for both subscales: 
7 to 8 for possible presence, 10 to 11 for probable presence, and 14 to 15 for severe anxiety or 
depression.   
Dermatology Life Quality Index 
The DLQI is a 10-item, validated questionnaire used in clinical practice and clinical trials to assess 
the impact of AD disease symptoms and treatment on QOL. The format is a simple response (0 to 
3 where 0 is “not at all” and 3 is “very much”) to 10 questions, which assess QOL over the past 
week, with an overall scoring system of 0 to 30; a high score is indicative of a poor QOL.   


XBIOTECH USA INC.            
 
PROTOCOL 2018-PT044 Version 3.0 
CONFIDENTIAL                                        22 August  2018                                            PAGE 39 of 52 
 
9.  ADVERSE EVENTS  
 
9.1 DEFINITION OF ADVERSE EVENT (AE) 
An adverse event is defined as any untoward medical occurrence in a subject participating in a 
clinical study that does not necessarily have a causal relationship with the pharmaceutical or 
biological agent under study.  An AE can therefore be any of the following: 
 
• 
Any unfavorable and unintended sign (including laboratory findings), symptom, or disease 
temporally associated with the use of bermekimab, whether or not it is apparently related to 
bermekimab 
• 
A concurrent illness 
• 
An exacerbation, or an unexpected increase in frequency or intensity of a preexisting 
condition, including intermittent or episodic conditions.  However, anticipated day-to-day 
fluctuations or expected progression of the preexisting condition (based upon the 
Investigator’s clinical judgment) are not to be considered AEs 
• 
A significant or unexpected worsening of the condition/indication under investigation.  
However, anticipated day-to-day fluctuations or expected progression of the disease under 
investigation (based upon the Investigator’s clinical judgment) are not to be considered AEs 
• 
A suspected interaction between the investigational drug and concomitant medications 
• 
Any clinically significant laboratory abnormality (including radiological interpretations, 
histopathological findings, etc.) 
 
9.2 DEFINITION OF SERIOUS ADVERSE EVENT (SAE) 
A serious adverse event is defined as any untoward medical occurrence that meets any of the 
following criteria:  
• 
Results in death 
• 
Life-threatening 
• 
Requires or prolongs inpatient hospitalization 
• 
Results in a persistent or significant disability 
• 
Congenital anomaly/birth defect 
• 
An important medical event that, while it may not result in death or be immediately life-
threatening or require/prolong hospitalization, may jeopardize the subject and/or may require 
medical or surgical intervention to prevent one of the outcomes listed above. Examples of 
such events are intensive treatment in an emergency room or at home for allergic 


XBIOTECH USA INC.            
 
PROTOCOL 2018-PT044 Version 3.0 
CONFIDENTIAL                                        22 August  2018                                            PAGE 40 of 52 
 
bronchospasm; blood dyscrasias or convulsions that do not result in hospitalization; or the 
development of drug dependency or drug abuse. 
 
Note that seriousness and severity should not be confused. A subject could experience a severe 
headache that would not qualify as an SAE, while another might experience a mild stroke that, 
while not severe, would be considered serious. 
 
9.3 RECORDING OF ADVERSE EVENTS 
All AEs and SAEs must be recorded on the case report form (CRF)/eCRF and in the patient’s 
source documents occurring between visit 1 (post-injection) and visit 9 (or if subject terminates 
from study prior to visit 9, seven days after the last administration of bermekimab).   
 
All AEs should be recorded in standard medical terminology as concisely as possible.  The AE 
recorded should not be a procedure or a clinical/laboratory measurement but should reflect the 
event leading to the procedure or the cause of the clinical/laboratory abnormality, if known.  
Whenever possible, AEs should be evaluated and recorded as a diagnosis, rather than individual 
signs and symptoms.  However, if a definitive diagnosis is not possible, the individual signs and 
symptoms should be recorded.  Any AE that worsens in intensity, or becomes serious, should be 
recorded as a new event. 
 
9.4 EVALUATING ADVERSE EVENTS 
All AEs will be graded according to the CTCAE version 4.03. 
 
9.5 ASSESSMENT OF CAUSALITY 
Investigators are required to assess the relationship, if any, of each AE or SAE to the investigational 
drug using clinical judgment to determine the degree of certainty with which an AE can be 
attributed to the investigational drug.  Alternative causes, such as natural history of the underlying 
disease, other risk factors, and the temporal relationship of the event to the administration of the 
study medication must be considered. 
 
Relationship to study drug is summarized as follows: 
• 
Not Related:  There is another obvious cause of the AE 
• 
Unlikely to be related:  There is another more likely cause of the AE 
• 
Possibly related:  The AE could have been due to the investigational drug 
• 
Probably related:  The AE is probably attributable to the investigational drug 


XBIOTECH USA INC.            
 
PROTOCOL 2018-PT044 Version 3.0 
CONFIDENTIAL                                        22 August  2018                                            PAGE 41 of 52 
 
• 
Definitely related:  The AE is most likely attributable to the investigational drug 
 
9.6 REPORTING REQUIREMENTS  
Any AE (with the exception of worsening AD symptoms or injection site reactions) of grade 2 or 
higher must be entered into the eCRF within 24 hours of learning of the event.  Any grade 3 or 
greater injection site reaction must be reported to the sponsor within 24 hours of learning of the 
event. 
 
All serious adverse events (SAEs) should be reported to the Sponsor within 24 hours of knowledge 
of the event.  These immediate reports should be followed promptly by detailed, written reports. 
The subject should be followed up with until stabilization of the reported SAE, either with full 
satisfactory resolution or resolution with sequelae, or until death of the subject.  Before declaring 
the subject is lost to follow-up, three unsuccessful attempts at contact should be made and recorded 
on the SAE form. The immediate and follow-up reports should identify subjects by unique code 
numbers assigned to the trial subjects rather than by the subjects' names, personal identification 
numbers, and/or addresses. The Investigator should also submit SAEs to the IRB/EC according to 
their IRB/EC guidelines [ICH-GCP E6].  Drug-related Serious Adverse Events will be reported to 
the FDA by XBiotech’s Medical Safety Officer according to 21 CFR 312.32. 
 
9.7 REFERENCE SAFETY INFORMATION:  POTENTIAL ADVERSE REACTIONS 
831 patients have been treated using bermekimab in patients with advanced solid tumors, advanced 
hematologic malignancies, metastatic colorectal cancer, peripheral vascular disease, type II 
diabetes, acne vulgaris, plaque psoriasis, and pyoderma gangrenosum.  Over 1200 doses of 
bermekimab were administered at 7.5 mg/kg to refractory, metastatic CRC patients with cancer 
associated symptoms at baseline (ECOG performance status 1 and 2).  In this trial (PT026), which 
is the largest controlled trial completed with bermekimab to date (N=309), patients were dosed at 
7.5 mg/kg for metastatic colorectal cancer.  The most common AEs reported (>10%) were 
abdominal pain, peripheral edema, fatigue, anemia, constipation, decrease in weight, asthenia, 
decreased appetite, and nausea.  The majority of these events were grade 1 or 2 and appeared to be 
related to the underlying CRC.  The prevalence of these events was similar in the bermekimab and 
placebo groups.  Two infusion reactions were reported in this trial, and they were not serious or 
severe (grade I or II). 
 


XBIOTECH USA INC.            
 
PROTOCOL 2018-PT044 Version 3.0 
CONFIDENTIAL                                        22 August  2018                                            PAGE 42 of 52 
 
 Bermekimab is a recombinant human IgG1 monoclonal antibody specific for human interleukin-
1α (IL-1α). As such, it is an immunomodulator that has anti-inflammatory and anti-neoplastic 
properties.  Other agents that could be considered in the same pharmacologic class include biologic 
agents that target IL-1 receptor antagonist and IL-1 beta.  Potential risks for agents in this class 
include infusion or injection site reactions, particularly with respect to IL-1ra, although in this case 
is likely related to the unanticipated agonist effects of the receptor antagonist when it is present in 
high local concentration at the site of injection and thus this effect is not relevant to bermekimab.  
 
Bermekimab is human monoclonal antibody derived immune plasma B cells derived from a natural 
human immune response against IL-1a.  Unlike previous generations of humanized or fully human 
antibodies, the entire bermekimab heavy and light chain sequences are identical to those found in 
naturally-occurring human IgG1κ, with the light and heavy chain variable regions being identical 
to those originally expressed by a peripheral blood B lymphocyte that was obtained from a healthy 
individual.  No in vitro affinity maturation or modifications have been made to improve its natural 
binding affinity (211 +/- 31 pM).  We believe that a true human antibody should be effectively non-
immunogenic in humans and thus exhibit optimal activity and pharmacokinetics.  To date, no 
treatment emergent anti-drug antibodies specific to bermekimab have been identified. 
 
The mechanism behind infusion reactions is not clear in all cases.  It may involve a reaction against 
the antibody, against excipients in the preparation such as polysorbate, or against some minor 
residual component from the manufacturing process (i.e. host cell proteins).  To date, there has 
been a very low incidence of mild injection site or infusion reactions observed (20 patients out of 
831 total; 2.4%).  All except two of these patients had grade 1 or 2 reactions that did not result in 
discontinuation.  In order to mitigate this class-specific risk, close monitoring is required during 
the bermekimab infusion and for at least 1 hour after infusion.  Availability of resuscitation 
equipment must be ensured.  Pre-medication with antihistamines or corticosteroids is not 
required. 
For the purposes of expedited safety reporting in clinical trials, the following should be considered 
expected events: 
• 
Infusion Related Reactions 
• 
Injection Site Reactions 
 
 
 


XBIOTECH USA INC.            
 
PROTOCOL 2018-PT044 Version 3.0 
CONFIDENTIAL                                        22 August  2018                                            PAGE 43 of 52 
 
10.  STATISTICAL PLAN 
 
This section provides the basis for the statistical analysis plan (SAP) for the study. The SAP may 
be revised during the study to accommodate amendments to the clinical study protocol, and to make 
changes to adapt to unexpected issues in study execution and data that may affect planned analyses.  
Analysis variables are listed in Section 8. 
 
10.1 STATISTICAL HYPOTHESIS 
No formal hypothesis tests will be performed for the primary endpoints. 
 
10.2 DETERMINATION OF SAMPLE SIZE 
The sample size chosen was one of convenience, and no formal sample size calculations were 
performed. 
 
10.3 ANALYSIS SETS 
10.3.1 Safety Analysis Sets 
The safety analysis set (SAF) consists of all patients that receive at least one dose of study 
medication and will be analyzed as treated. 
 
The secondary endpoints will be analyzed based upon the SAF, as well as the per protocol 
population (PP).  The per protocol population will consist of those patients that complete both the 
baseline and visit 8 assessments of their atopic disease (as specified for the secondary endpoints). 
 
10.4 PATIENT DISPOSITION 
A listing of all patients prematurely discontinued from the study, along with reasons for 
discontinuation will be provided. In addition, the total number of patients for each of the 
following categories will be summarized. 
 
• 
The total number of screened patients: met the inclusion criteria regarding the target 
indication and signed the informed consent 
• 
The total number of enrolled patients: met all inclusion/exclusion criteria and receive at 
least one dose of therapy 
• 
The analysis sets (SAF, PP) 
• 
The total number of patients who discontinued the study, and the reasons for 
discontinuation 


XBIOTECH USA INC.            
 
PROTOCOL 2018-PT044 Version 3.0 
CONFIDENTIAL                                        22 August  2018                                            PAGE 44 of 52 
 
• 
A listing of patients prematurely discontinued from treatment, along with reasons for 
discontinuation 
 
10.5 STATISTICAL METHODS 
All analyses will be summarized using descriptive statistics and data will be presented in tabular 
format for each treatment group and pooling all bermekimab dose groups together. Continuous data 
will be summarized for each treatment group using the number of observations available (N), 
means, standard deviation (SD), minimums, medians, and maximums.  Categorical data will be 
summarized for each treatment group using counts and percentages.  Missing data will not be 
categorized in the summaries. 
10.5.1 Handling Missing Data 
If baseline assessment is not available, the baseline value will remain missing. The subject will not 
be included in baseline summaries.  
10.5.2 Adjustment for Multiple Comparisons 
No adjustment for multiple comparisons will be made. 
10.5.3 Demography and Baseline Characteristics 
Demographic and baseline characteristics will be summarized descriptively by treatment group.  
Continuous variables will be summarized with mean, median, SD, minimum, and maximum.  
Categorical variables will be summarized with frequency and percentage. 
10.5.4 Efficacy Analysis 
All primary and secondary efficacy analyses will be performed for SAF and PP populations. 
Summary statistics will be provided to evaluate the overall treatment effect and effect within the 
treatment group. No statistical comparison of differences will be performed across bermekimab  
dose groups. 
 
Change from baseline to visit 8 will be summarized using descriptive statistics. Corresponding 95% 
confidence interval of the point estimate of mean change will be provided by treatment group and 
for overall pooled population. The number and percent of subjects achieving the response (as 
specified for the secondary endpoints) will be summarized by treatment groups and overall 
population along with 95% confidence interval for the point estimate. Number and percent of 
patients achieving response in EASI, and SCORAD core from baseline at visit 8, will be reported 
separately, along with 95% confidence interval for 50% or greater reduction.  


XBIOTECH USA INC.            
 
PROTOCOL 2018-PT044 Version 3.0 
CONFIDENTIAL                                        22 August  2018                                            PAGE 45 of 52 
 
 
10.6 SAFETY ANALYSIS 
The safety analysis will be based on the SAF. This includes reported AEs and other safety 
information (ie, clinical laboratory evaluations and vital signs).  A summary of safety results will 
be presented for each treatment group. 
 
10.6.1 Analysis of Adverse Events 
Adverse events reported in this study will be coded using the currently available version of 
MedDRA. Coding will be to lowest level terms. The verbatim text, the PT, and the primary SOC 
will be listed in patient listings. 
 
Pre-treatment AEs are defined as those that develop or worsen in severity from the time the patient 
provides informed consent, prior to the first dose of study drug.  Treatment emergent AEs (TEAEs) 
are defined as AEs that develop or worsen in severity following the first dose of study drug through 
the last study visit. 
 
The number and percentage of patients experiencing AEs and TEAEs will be summarized by 
seriousness (SAEs), severity (grades 1-5), SOC, and PT. 
 
10.6.2 Other Safety 
 
Vital Signs 
Summaries of vital sign parameters by treatment group will include: 
• 
Each vital sign parameter and change from baseline 
• 
The number (n) and percentage (%) of patients with grade 2 or greater vital sign AEs 
• 
Listings will be provided with flags indicating the AE grade 
 
Laboratory Tests 
Clinical laboratory values will be converted to standard international units. Summaries of 
laboratory variables by treatment group will include: 
• 
Each laboratory result and change from baseline 
• 
The number (n) and percentage (%) of patients with grade 2 or greater laboratory AEs 
• 
Listings will be provided with flags indicating the out-of-laboratory-range values as well 


XBIOTECH USA INC.            
 
PROTOCOL 2018-PT044 Version 3.0 
CONFIDENTIAL                                        22 August  2018                                            PAGE 46 of 52 
 
as the AE grade. 
 
Electrocardiogram 
12- Lead ECG analyses 
Summaries of 12-lead ECG parameters by treatment group will include: 
• 
ECG status (ie, normal, abnormal, clinically significant) 
 
10.7 PK ANALYSIS 
Pharmacokinetic analysis of plasma concentrations of bermekimab will be performed for the PK 
population using non-compartmental model. Standard PK parameters such as maximum 
concentration (Cmax) and its occurrence (Tmax), average concentration at steady state (Cavg), area 
under concentration version time curve from time 0 to selected time point (AUC0-t), elimination 
rate constant (Kel) and half-life (T1/2), will be presented. Other non-compartmental PK parameter 
values, as considered appropriate, will be calculated.  
 
10.7.1 Treatment Exposure 
The duration of exposure during the study will be presented by treatment and calculated as:   
(Date of last study drug injection – date of first study drug injection) + 7 
 
The number (%) of patients and exposed to study drug will be presented by specific time periods 
for each treatment group. The time periods of interest will be specified in the SAP. 
 
In addition, duration of exposure during the study will be summarized for each treatment group 
using number of patients, means, SD, minimums, medians, and maximums. 
 
A summary of the number of doses, and dose volume by treatment arm will be provided. 
 
 
 
 
 
 
 
 


XBIOTECH USA INC.            
 
PROTOCOL 2018-PT044 Version 3.0 
CONFIDENTIAL                                        22 August  2018                                            PAGE 47 of 52 
 
11.  STUDY MANAGEMENT AND ADMINISTRATION 
 
11.1 ETHICAL CONDUCT OF STUDY (GCP) 
The guidelines of the World Medical Association Declaration of Helsinki in its revised edition (48th 
General Assembly, Somerset West, Republic of South Africa, October 1996), the guidelines of ICH 
GCP (CPMP/ICH/135/95), as well as the demands of national drug and data protection laws and 
other applicable regulatory requirements, will be strictly followed.  Approval will be obtained from 
the appropriate regulatory authorities before sites are initiated.  
 
11.2 IRB AND ETHICS COMMITTEE APPROVAL  
Prior to initiation of the study, the protocol, the informed consent form, the subject information 
sheet(s), details of the subject recruitment procedures and any other relevant study documentation 
will be submitted to the responsible IRB or Ethics Committee (EC).  The Investigator will report 
promptly to the IRB/EC any new information that may adversely affect the safety of subjects or the 
conduct of the study. Similarly, the Investigator will submit written summaries of the study status 
to the IRB/EC annually, or more frequently if requested by the IRB/EC.  Upon completion of the 
study, the Investigator will provide the IRB/EC with a brief report of the outcome of the study, if 
required. 
 
11.3 PROTOCOL MODIFICATIONS  
Modifications of the signed protocol are only possible by approved protocol amendments and with 
the agreement of all responsible persons.  The procedure for approval of a protocol amendment is 
identical to that for approval of the protocol.  The IRB/EC must be informed of all protocol 
amendments and should be asked for its opinion as to whether a full re-evaluation of the ethical 
aspects of the study is necessary by the committee.  This should be fully documented.  The 
Investigator must not implement any deviation from or change to the protocol, without discussion 
with an agreement by the study Sponsor and prior review and documented approval/favorable 
opinion of the amendment from the relevant IRB/EC, except where it is necessary to eliminate an 
immediate hazard to study subjects, or where the change(s) involves only logistical or 
administrative aspects of the study (e.g., change in CRA(s), change of telephone number(s)). 
Protocol amendments will be submitted to the appropriate authority(ies) as required by the 
applicable regulatory requirement(s). 
 


XBIOTECH USA INC.            
 
PROTOCOL 2018-PT044 Version 3.0 
CONFIDENTIAL                                        22 August  2018                                            PAGE 48 of 52 
 
11.4 SUBJECT INFORMATION AND CONSENT  
The Investigator is responsible for ensuring that no subject will receive any study-related 
examination or activity before that subject has given an IRB/EC approved informed consent.  The 
subject must give written consent after the receipt of detailed information.  The verbal explanation 
will cover all the elements specified in the written information provided for the subject.  The 
Investigator will inform the subject of the aims, methods, anticipated benefits and potential hazards 
of the study, including any discomfort it may entail.  The subject must be given every opportunity 
to clarify any points he/she does not understand and if necessary, ask for more information.  At the 
end of the interview, the subject may be given time to reflect if this is required, or if the subject 
requests more time.  Subjects and/or legal guardian forms will be kept and archived by the 
Investigator in the Investigator's study file.  It should be emphasized that the subject is at liberty to 
withdraw their consent to participate at any time, without penalty or loss of benefits to which the 
subject is otherwise entitled.  Subjects who refuse to give, or withdraw, written informed consent 
may not be included or continued in this study, but this will not impact their subsequent care.  The 
Investigator will notify in writing each subject’s primary care physician (or equivalent) of the 
subject’s intent to participate in the study. 
 
11.5 DATA PROTECTION AND CONFIDENTIALITY  
By signing the final protocol, every participating Investigator agrees to keep all information and 
results concerning the study and the investigational product confidential.  The confidentiality 
obligation applies to all personnel involved at the investigational site.  The Investigator must ensure 
that each participant’s anonymity will be maintained in accordance with applicable laws. On eCRFs 
or other documents submitted to the Sponsor, subjects should not be identified by their name, but 
by subject ID number.  The Investigator should keep a separate log of ID numbers, names and 
addresses.  Documents that contain the names associated with these ID numbers (e.g., written 
consent/assent forms), are not for submission to the Sponsor and should be maintained by the 
Investigator in strict confidence except to the extent necessary to allow auditing by regulatory 
authorities, auditing or monitoring by the Institutional Review Board/EC, the Sponsor personnel or 
their affiliates and designees (such as CRAs).  
Copies of radiological scans and autopsy reports (and other documents) that may be requested by 
the Sponsor should be de-identified.  The Investigator shall obtain all such permissions and 
authorizations as may be necessary or desirable to allow the collection and use of information 
protected under federal privacy laws and state privacy laws, including permission/authorization for 
monitoring and analysis (including re-analysis in combination with results of other studies), for 


XBIOTECH USA INC.            
 
PROTOCOL 2018-PT044 Version 3.0 
CONFIDENTIAL                                        22 August  2018                                            PAGE 49 of 52 
 
regulatory submission purposes and for applicable reporting (if any) required to be made by 
Sponsor, its affiliates and their designee.  
 
11.6 STUDY REPORT AND PUBLICATIONS  
A final integrated clinical/statistical report will be prepared that is compliant with the ICH 
Harmonized Tripartite Guideline: Structure and Content of Clinical Study Reports 
(CPMP/ICH/137/95).  The results of this study will be published and/or presented at scientific 
meetings in a timely manner.  The publication policy is described in the contract between the 
Sponsor and Investigator.  
 
11.7 STUDY FILES AND RETENTION OF RECORDS  
Copies of all study documents should be retained by the Investigator until at least two years after 
the last approval of a marketing application in an ICH region and until there are no pending or 
contemplated marketing applications in an ICH region or at least two years have elapsed since the 
formal discontinuation of clinical development of the investigational product, in accordance with 
21 CFR 312.62.  These documents should be retained for a longer period however, if required by 
regulatory requirements or by agreement with the Sponsor.  It is the responsibility of the Sponsor 
to inform the Investigator/institution as to when these documents no longer need to be retained. 
The final database will be archived according to the regulatory requirements.  
 
11.8 CASE REPORT FORMS  
Data for this protocol will be captured electronically in an Electronic Data Capture (EDC) system.  
Designated study personnel will be provided unique user names and passwords.  Each study 
personnel will have specific access within the electronic data collection system based on their role. 
The EDC system contains an audit trail associated with each individual's unique password that will 
document date and time of data entry and revisions.  All protocol-specified data is to be entered 
into the EDC system in a timely manner for review and audit by XBiotech.  All data is to be entered 
such that it will allow accurate interpretation and tabulation.  It is the Investigator's responsibility 
to ensure that all discontinued orders or changes in study or other medications entered into the 
database correspond to entries in the subject's medical records (i.e. source documents) and to 
acknowledge accurate completion of the eCRF. 
 
11.9 DRUG ACCOUNTABILITY  
A Drug Dispensing Log must be kept current and should contain the following information:  


XBIOTECH USA INC.            
 
PROTOCOL 2018-PT044 Version 3.0 
CONFIDENTIAL                                        22 August  2018                                            PAGE 50 of 52 
 
• 
Initial inventory upon receipt of supplies at the study site  
• 
Identification number of each subject to whom test drug was administered  
• 
Date(s), quantities, lot numbers and calculations for all test drugs administered  
• 
Final inventory (upon completion of the study) 
This inventory must be available for inspection by the Clinical Research Associate.  The 
Investigator (or pharmacist, as appropriate) must maintain records of the delivery of the study 
medication to the study site, the inventory at the site, the usage for each subject, and destruction. 
The inventory must be available for monitoring, auditing or inspection.  A drug dispensing log must 
be kept current and should contain the following information:  
• 
The subject identification number to whom the drug is dispensed  
• 
The lot number of the drug dispensed  
• 
The date(s) and the quantity of the drug dispensed to the subject 
 
11.10   INSPECTIONS  
Investigator sites, the study database and study documentation may be subject to quality assurance 
audits during the course of the study either by the Sponsor or their appointed representatives.  In 
addition, regulatory bodies at their discretion may conduct inspections.  The Investigator shall 
permit the authorized Sponsor, agents of the Sponsor, and regulatory agency employees to enter 
and inspect any site where the drug or records pertaining to the drug are held, and to inspect all 
records relating to an investigation, including subject records.  The Sponsor will not, however, copy 
any source data from the patient’s dossier.  Completed eCRFs must be made available by the 
Investigator for review by the Sponsor, agents of the Sponsor, the CRA and the regulatory agencies.  
To ensure the accuracy of data submitted, it is mandatory that representatives of the Sponsor and 
of the regulatory agencies have direct access to source documents (e.g., subject medical records, 
charts, laboratory reports, etc.).  Subject confidentiality will be protected at all times.  
 
11.11 ACCESS TO INFORMATION FOR MONITORING  
CRAs will establish and maintain regular contact between the Investigator and the Sponsor.  CRAs 
will evaluate the competence the study center, informing the Sponsor about any problems relating 
to facilities, technical equipment or medical staff. During the study, CRAs will check that written 
informed consent has been obtained from all subjects correctly and that data are recorded correctly 
and completely.  CRAs are also entitled to compare entries in eCRFs with corresponding source 
data and to inform the Investigator of any errors or omissions.  CRAs will also monitor adherence 
to the protocol at the Investigator site.  They will arrange for the supply of investigational product 


XBIOTECH USA INC.            
 
PROTOCOL 2018-PT044 Version 3.0 
CONFIDENTIAL                                        22 August  2018                                            PAGE 51 of 52 
 
and ensure appropriate storage conditions are maintained. The CRA will make written reports to 
the Sponsor on each occasion when contact with the Investigator is made, regardless of whether it 
is by phone or in person.  During monitoring visits, entries in the eCRFs will be compared with the 
original source documents.  The Investigator must agree to meet with the CRA at regular intervals 
and to cooperate in resolving any queries or findings made during the monitoring process.  
 
11.12 STUDY DISCONTINUATION  
If the study is prematurely terminated or suspended, the Sponsor will promptly inform the 
Investigators/institutions and the regulatory authority(ies) of the termination or suspension and the 
reason(s) for the termination or suspension.  The IRB/EC will also be promptly informed and 
provided with the reason(s) for the termination or suspension by the Sponsor or by the 
Investigator/institution, as specified by the applicable regulatory requirement(s). 
 


XBIOTECH USA INC.            
 
PROTOCOL 2018-PT044 Version 3.0 
CONFIDENTIAL                                        22 August  2018                                            PAGE 52 of 52 
 
REFERENCES 
1  Coleman KM, Gudjonsson JE, Stecher M.  Open-Label Trial of MABp1, a True Human Monoclonal Antibody 
Targeting Interleukin 1α, for the Treatment of Psoriasis.  JAMA Dermatol. 2015 May;151(5):555-6. doi: 
10.1001/jamadermatol.2014.5391. 
2 Carrasco D, Stecher M, Lefebvre GC, Logan AC, Moy R.  An Open Label, Phase 2 Study of MABp1 
Monotherapy for the Treatment of Acne Vulgaris and Psychiatric Comorbidity.  J Drugs Dermatol. 2015 
Jun;14(6):560-4. 
3 Kanni T et al. MABp1 Targeting Interleukin-1Alpha for Moderate to Severe Hidradenitis Suppurativa not 
Eligible for Adalimumab: A Randomized Study. J Invest Dermatol. 2017 Nov 9.  
4 Miossec. Anti-interleukin 1α autoantibodies. Ann Rheum Dis 2002; 61: 577-579. 
5 Gallay et al. Characterization and detection of naturally occurring antibodies against IL-1α and IL-1β in 
normal human plasma. Eur Cytokine Network 1991; 2: 329-338. 
6 Suzuki et al. Anti- IL-1α autoantibodies in patients with rheumatic diseases and in healthy subjects. Clin Exp 
Immunol 1991; 85: 407-412. 
7 Saurat et al. Anti-IL-1α autoantibodies in humans: characterization, isotype distribution, and receptor-binding 
inhibition—higher frequency in Schnitzler’s syndrome (urticaria and macroglobulinemia). J Allergy Clin 
Immunol 1991; 88: 244-256. 
8 Bou-Dargham MJ et al. The Role of Interleukin-1 in Inflammatory and Malignant Human Skin Diseases and 
the Rationale for Targeting Interleukin-1 Alpha. Med Res Rev. 2017 Jan;37(1):180-216. 
9 Han et al.  Interleukin-1alpha-induced proteolytic activation of metalloproteinase-9 by human skin. Surgery. 
2005 Nov;138(5):932-9. 
10Askentijevich et al. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. 
N Engl J Med. 2009 Jun 4;360(23):2426-37. 
11 Jang et al.  Mass spectrometric quantification of neutral and sialylated N-glycans from a recombinant 
therapeutic glycoprotein produced in Chinese hamster ovary cell lines. Anal. Biochem. 386 (2009) 228-236. 
12 Miossec. Anti-interleukin 1α autoantibodies. Ann Rheum Dis 2002; 61: 577-579. 
13 Gallay et al. Characterization and detection of naturally occurring antibodies against IL-1α and IL-1β in 
normal human plasma. Eur Cytokine Network 1991; 2: 329-338. 
14 Müller et al. Autoantibodies to IL-1α in sera from umbilical cords, children, and adults, and from patients 
with juvenile chronic arthritis. Scand J Rheumatol. 1996; 25 (3): 164-7 
15 Svenson et al. Distribution and characterization of autoantibodies to interleukin 1 alpha in normal human 
sera. Scand J Immunol. 1990: 32 (6): 695-701